



**Liver cancer survival in the United States by race and stage
(2001-2009): findings from the CONCORD -2 study.**

| | |
|-------------------------------|---|
| Journal: | <i>Cancer</i> |
| Manuscript ID | CNCR-17-0457.R1 |
| Wiley - Manuscript type: | Supplement Article |
| Date Submitted by the Author: | 16-May-2017 |
| Complete List of Authors: | Momin, Behnoosh; Centers for Disease Control and Prevention, Division of Cancer Prevention and Control Pinheiro, Paulo; University of Nevada Las Vegas, Carreira, Helena; London School of Hygiene and Tropical Medicine Li, Chunyu; CDC, Weir, H.K.; Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion |
| Keywords: | liver cancer, population-based survival, NPCR, SEER, cancer control |
| | |

1
2
3 **Liver cancer survival in the United States by race and stage (2001-2009): findings from the**
4 **CONCORD -2 study.**
5
6

7 **Running Title:** Liver cancer survival in the US by race and stage
8

9 **Authors:** Behnoosh R. Momin, DrPH, MS, MPH¹; Paulo S. Pinheiro, MD, PhD²; Helena
10 Carreira, MSc³, Chunyu Li, MD, PhD, MS¹, Hannah K Weir, PhD¹
11

12 **Affiliations:**

13
14 ¹Division of Cancer Prevention and Control, Centers for Disease Control and Prevention,
15 Atlanta, GA

16 ² Epidemiology and Biostatistics, University of Nevada Las Vegas, Las Vegas, NV

17 ³ Cancer Research UK Cancer Survival Group, Department of Non-Communicable Disease
18 Epidemiology, London School of Hygiene & Tropical Medicine, London, UK
19
20
21

22 **Corresponding Author:**

23 **Dr. Behnoosh R. Momin**

24 4770 Buford Highway, MS F-76

25 Atlanta, GA 30341

26 Telephone: (770) 488-3112

27 Email: BMomin@cdc.gov

28 Fax: (770) 488-4335
29
30

31 Number of pages: 20

32 Text words: 3,864

33 Number of figures/tables: 5
34
35
36
37

38 **Precis:** Some progress has occurred in survival for liver cancer, but 5-year survival remains low,
39 even for those diagnosed at localized stage. Given the low survival observed in all states, efforts
40 directed at controlling well-established risk factors, such as hepatitis B may have the greatest
41 impact on reducing the burden of liver cancer in the United States.
42

43 **DISCLAIMER:** The findings and conclusions in this report are those of the authors and do not
44 necessarily reflect the official position of the Centers for Disease Control and Prevention.
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Abstract

Background. Worldwide, liver cancer is a leading cause of death for both men and women. The number of Americans who are diagnosed with liver cancer and die from it has been rising slowly each year. We examined population-based survival, by state, race, and stage at diagnosis, using data from the CONCORD-2 study. **Methods.** We analyzed data from 37 state-wide registries, covering approximately 80% of the US population, for patients diagnosed during 2001-2009. Survival up to five years was adjusted for background mortality (net survival) using state- and race-specific life tables, and age-standardized using the International Cancer Survival Standard (ICSS) weights. **Results.** Liver cancer was diagnosed overall more often at the localized stage, with blacks being more often diagnosed at distant and regional stages than whites. Overall 5-year net survival was 12.2% in 2001-2003 and 14.8% in 2004-2009. Whites had higher survival than blacks in both calendar periods (11.7% vs. 9.1% and 14.3% vs. 11.4%, respectively). During 2004-2009, 5-year survival was 25.7% for localized stage, 9.5% for regional stage, and 3.5% for distant stage. **Conclusion.** Some progress has occurred in survival for liver cancer, but 5-year survival remains low, even for those diagnosed at localized stage. Efforts directed at controlling well-established risk factors such as hepatitis B may have the greatest impact on reducing the burden of liver cancer in the US.

Keywords: cancer registries, survival, liver, hepatitis

Introduction

Worldwide, liver cancer is the fifth most common cancer among men, the ninth most common cancer among women, and the second most common cause of cancer death for men and women combined (1). Recent reports from North America, Europe, and Japan showed that the incidence of hepatocellular carcinoma (HCC), the most common histological type, is increasing (2-5). The number of Americans who are diagnosed with and die from liver cancer each year has been rising slowly for several decades (6). In 2013, 21,143 men and 8,330 women were diagnosed with liver cancer, and 16,300 men and 7,732 women died from liver cancer (7). According to the 2015 Annual Report to the Nation, United States (US) death rates for most cancer sites declined or were stable from 2003 to 2012 among men and women of each racial and ethnic, except for liver cancer, which increased for most racial and ethnic groups (8). Among men and women, US liver cancer incidence rates were highest among American Indian/Alaskan Natives, followed by Asian Pacific Islanders, and Hispanics. Liver cancer incidence rates among US men were more than twice those among US women (8).

Chronic hepatitis B (HBV), Chronic hepatitis C (HCV), and cirrhosis all contribute to the risks associated with hepatocellular carcinoma. HBV and HCV infections account for an estimated 78% of global HCC cases (9). In addition, excessive alcohol consumption, obesity, rare metabolic disorders, type 2 diabetes mellitus, and non-alcoholic fatty liver disease (NAFLD) are other known risk factors of liver cancer (10). Most cases of HCC are preventable. Methods to reduce the risk of liver cancer include evidence-based strategies or interventions related to the risks associated with hepatitis. Vaccination against hepatitis B infection for all infants at birth

1
2
3 and adults who may be at an increased risk, as well as testing for hepatitis C and linking patients
4
5 to follow-up care after testing, leads to declines in HCC incidence (8).
6
7

8 In contrast to many other cancers, the prognosis of patients with HCC is not highly correlated
9
10 with tumor stage. Cirrhosis underlies the neoplasm in most cases and has major impact on the
11
12 prognosis of patients with HCC (11). The CONCORD-2 study reported survival for patients
13
14 with cancer diagnosed from 1995 through 2009 in 67 countries, and enabled the comparison of
15
16 survival of patients in the United States (US) with other countries (12). Liver cancer survival
17
18 was low in all countries. The 5-year age-standardized net survival from liver cancer was below
19
20 20% everywhere in Europe, in the range 15–19% in North America, and as low as 7–9% in
21
22 Mongolia and Thailand. Between 1995-99 and 2005-2009, five-year age-standardized net
23
24 survival from liver cancer increased in the United States from 9% to 15%. This could possibly be
25
26 due to improved viral hepatitis services and medical management.
27
28
29
30
31

32
33
34 The purpose of the current study is to expand the CONCORD-2 study by reporting liver cancer
35
36 survival in the United States using the largest data set available (80% US coverage), by race and
37
38 stage at diagnosis, using available population-based registry data from 37 states. This
39
40 information is critical to prioritizing, planning and implementation of cancer control
41
42 interventions.
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Material and Methods

Data Source and Variables

Thirty-seven (37) state cancer registries affiliated with the National Program of Cancer Registries (NPCR) or the Surveillance, Epidemiology and End Results (SEER) Programs that participated in the CONCORD-2 study, (12) covering approximately 80% of the US population, agreed to the inclusion of their data in these analyses. We analyzed individual tumor records for 126,261 adults (aged 15-99 years) who were diagnosed with cancer of the liver and intrahepatic bile ducts (ICD-O-3 codes C22.0-C22.1) (13) during 2001-2009 and followed up through December 31, 2009. We included the first primary, invasive cancer of the liver, regardless of whether an individual had a previous cancer. If an individual was diagnosed with two or more cancers of the liver during 2001 through 2009, only the first was considered in the survival analysis.

We grouped patients by year of diagnosis into two calendar periods (2001-2003 and 2004-2009) to reflect changes in the methods used by US registries to collect SEER Summary Stage (SS) 2000 at diagnosis (14). During 2001-2003, most registries coded stage SS2000 directly from the medical records. During 2004-2009, all registries derived SS2000 using the Collaborative Staging System (15).

Survival analyses

We analysed survival by state, race (all, black, white), SS2000 (local, regional, distant, unknown) and calendar period of diagnosis. We estimated net survival up to 5 years after diagnosis, with 95% confidence intervals (CI), using the Pohar Perme estimator (16) of net survival. Net survival can be interpreted as the probability of survival up to a given time since

1
2
3 diagnosis, after controlling for other causes of death (background mortality). To control for the
4 wide differences in background mortality between participating registries, we constructed life
5 tables (17) of all-cause mortality in the general population of each state from the number of
6 deaths and the population, by a single year of age, sex, calendar year, and where possible, by
7 race (black, white), using a flexible Poisson model (18).

8
9
10 We estimated net survival using the cohort approach for patients diagnosed in 2001-2003, since
11 all patients had been followed up for at least five years by December 31, 2009. We used the
12 complete approach to estimate net survival for patients diagnosed from 2004-2009, because five
13 years of follow-up data were not available for all patients. Net survival was estimated for five
14 age groups (15-44, 45-54, 55-64, 65-74, 75-99 years). We obtained age-standardized survival
15 estimates using the International Cancer Survival Standard (ICSS) weights (19). If two or more
16 of the five age-specific estimates could not be obtained, we present only the pooled,
17 unstandardized survival estimates for all ages combined. Unstandardized estimates are italicized
18 in the tables. Trends, geographic variations and differences in age-standardized survival by race
19 are presented graphically in bar-charts and funnel plots (20). Funnel plots of net survival for
20 2001-2003 and 2004-2009 provide insight into the variability of cancer survival in the US by
21 race and state and show how much a particular survival estimate deviates from the pooled
22 estimate of US registries (horizontal line) given the precision of each estimate. More details on
23 data and methods are provided in the accompanying article (21).

52 **Results**

53
54 Liver cancer case distribution by race, state of residence, and stage at diagnosis by calendar
55 period of diagnosis is reported in Table 1. In 2004-2009, liver cancer was mostly diagnosed at

1
2
3 localized stage (overall 41%), followed by regional (24%) and distant (18%). Stage at diagnosis
4
5 varied slightly by race, with blacks being most often diagnosed at distant and regional stages
6
7 (20% and 26%, respectively, compared to 17% and 24% in whites). However, state-specific
8
9 analyses showed that patients with unknown stage at diagnosis ranged from 8% to 30%, which
10
11 makes accurate comparisons across race at the national level difficult (Supplemental Table 1).
12
13 Between the two calendar periods, there is indication of a shift towards earlier diagnosis of liver
14
15 cancer, with an additional 8 percentage points in localized stage and 2 percentage points in
16
17 regional stage, and a less than 1 percentage point increase in patients diagnosed with distant
18
19 stage. Additionally, there was a substantial decline in the proportion of cases recorded with
20
21 unknown stage at diagnosis, from 26% to 17%.
22
23
24
25
26
27
28

29 Although the overall 5-year age-standardized net survival was low, 12% in 2001-2003 and 15%
30
31 in 2004-2009, an improvement between the two calendar periods was observed (Figure 1). Of the
32
33 35 states for which an age-standardized estimates were available, net survival increased between
34
35 2001-2003 and 2004-2009 in 30 states, while only 5 states showed a decrease. There was
36
37 considerable variation by state in 2004-2009 in the 5-year survival, ranging from 8.1% in
38
39 Wyoming to 20.9% in Florida (Supplemental Table 2).
40
41
42
43
44
45

46 One-, 3-, and 5-year age-standardized net survival in 2004-2009 was 38%, 21%, 15%,
47
48 respectively (Table 2). For each of the three time points, blacks showed lower age-standardized
49
50 net survival than whites for all states combined. The difference was most pronounced in the first
51
52 year after diagnosis, suggesting that blacks have a lower survival in the short term in addition to
53
54 lower survival at five years since diagnosis. Only four states showed considerable in-state racial
55
56
57
58
59
60

1
2
3 disparities, all with a survival disadvantage for blacks compared to whites. There was, however,
4 a 5-year survival improvement for both races from 2001-2003 to 2004-2009, 2.6 percentage
5 point increase for whites, and 2.3 percentage points for blacks. Five-year age-standardized net
6 survival was 14.3% for whites and 11.4% for blacks. Overall 5-year survival for all races
7 combined was 14.8%, higher than both blacks and whites.
8
9

10
11
12
13
14
15
16
17 Five-year age-standardized net survival by stage (Table 3) for 2004-2009 was uniformly low at
18 26%, 10% and 4% for localized, regional and distant stage, respectively. For localized stage,
19 increases in survival were observed between 2001-2003 and 2004-2009 with a 2.8 percentage
20 points for all races, 2.4 percentage points for whites and 5.0 percentage points for blacks. For
21 regional and distant stages, smaller increases were observed, except that for blacks diagnosed
22 with regional stage, for whom there was a decline in survival of 1 percentage point. While 5-year
23 net survival was low in all states, there was considerable variation by stage and state
24 (Supplemental Table 3).
25
26
27
28
29
30
31
32
33
34
35

36
37
38
39 Figure 2 shows funnel plots of net survival for 2001-2003 and 2004-2009, to obtain further
40 insight into the variability of liver survival in the US, by race and state. Although survival for
41 liver cancer was generally low in all states in both calendar periods, survival for black patients
42 was lower than survival for white patients, and in most states it was lower than the pooled U.S.
43 value.
44
45
46
47
48
49

50 51 **Discussion**

52
53
54 This study reports the most comprehensive comparison of trends in the United States in 5-year
55 survival for liver cancer, using recent population-based data. The 5-year age-standardized net
56
57
58
59
60

1
2
3 survival for liver cancer reported in this analysis was low (15%) for the most recent period, but
4 slightly higher than in 2001-2003 (12%). This slight increase may be partially explained by the
5 increased proportion of patients diagnosed at localized stage who showed improved survival in
6 the most recent years. Five-year survival in the US is slightly lower but still closely aligned with
7 the 5-year survival estimates of Canada (17.7% [16.8-18.7%], 2005-2009) and slightly higher
8 than survival in the United Kingdom (9.3% [8.7-9.9%], 2005-2009) (12). This study noted some
9 variations in survival by state, race, and sex. Whites had higher survival than blacks in both
10 calendar periods. Additionally, white women showed a survival rate that was 2.5 percentage
11 points higher than white men, and black women showed a survival rate that was 5.5 percentage
12 points higher than black men. While our findings report a survival advantage for women, this is
13 in contrast to those reported for Europe in the late 1990s (22). Micheli and colleagues reported
14 an advantage for women for 11 of the 26 cancer sites; this advantage was not reported for liver
15 cancer. This difference may reflect a difference in US and European populations. Regardless of
16 state, variations in liver cancer survival by race and gender are unknown, liver cancer is
17 uniformly fatal across all populations. Early diagnosis for liver cancer is challenging, since
18 many of the symptoms associated with this disease do not present until later stages. In addition,
19 due to the location of the liver beneath the rib cage, liver tumors are difficult to detect.
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45

46 This study suggests there is some improvement in liver cancer survival. Advances in treatment
47 strategies likely contributed to this improvement. Surgical resection, liver transplantation, and
48 ablation are associated with best long-term survival. Surgical resection is usually performed in
49 patients with localized HCC and sufficient preserved liver function. Liver transplantation is the
50 best option for patients with decompensated cirrhosis and a solitary lesion (<5 cm) or early
51
52
53
54
55
56
57
58
59
60

1
2
3 multifocal disease (≤ 3 lesions, ≤ 3 cm in diameter) (23). When liver resection or transplantation is
4
5 feasible, ablation may be used, particularly for patients with early-stage HCC that is centrally
6
7 located in the liver. Disparities in access to and receipt of appropriate surgical care may play an
8
9 essential role for the racial differences we observed in liver cancer survival. Studies have shown
10
11 that African Americans and Asians with localized HCC were significantly less likely to receive a
12
13 transplant compared to their white counterpart (24). In addition, African American patients were
14
15 found to be younger and have a more advanced stage of disease than white patients, and were
16
17 also more likely to die while waiting for a transplant (25). However, survival disparities by race
18
19 may not be explained by differences in care only. Artinyan and colleagues reported that racial
20
21 differences in survival remained significant among patients who received liver transplantation
22
23
24
25
26
27 (26).

31 *Clinical Implications*

32
33 To improve liver cancer survival, adherence to evidence-based treatment protocols among all
34
35 populations, as well as other factors including biologic factors, response to therapy, patient
36
37 comorbidities, post-treatment follow-up and care, and tumor recurrence all need to be
38
39 considered. Increased recruitment of non-white populations to liver cancer clinical trials may
40
41 help alleviate racial differences in survival and improve the understanding of race-based
42
43 differences in cancer biology (27). HBV or HCV can cause persistent active hepatitis and
44
45 hepatic fibrosis, which lead to the development of HCC and also has major impact on the
46
47 prognosis of patients with HCC by affecting the rate of recurrence after surgery (28-30).
48
49 Interferon therapy has shown to be beneficial for patients with hepatitis virus-associated HCC
50
51 and can improve their outcome after curative resection (31).
52
53
54
55
56
57
58
59
60

Cancer Control Implications

Given that most liver cancers are preventable (CDC), cancer control efforts and resources that support preventing infection and promoting viral hepatitis services should be prioritized (32-33). Approximately 22% of HCC among those aged 65 years or older in the United States is attributed to HCV, (10) and an estimated 1.6 million persons will be eligible for HCV treatment by 2020 (34). Antiviral therapies for hepatitis B and hepatitis C can help prevent liver cancer, and also result in decreased neuroinflammation in the liver and over time cause reversal of fibrosis, which also leads to decreased HCC risk (35). In 2012, the CDC recommended one-time HCV testing for persons born during 1945–1965 (aged 47–67 years in 2012) (36). The following year, the US Preventive Services Task Force issued similar recommendations (37). According to the National Academies of Science, Engineering, and Medicine (38), limited public and provider awareness, as well as limited public resource allocation are the primary underlying causes of high rates of chronic hepatitis B and C in the United States (38). In the U.S., Asians have the highest incidence of HBV (39). However, for other populations (non-Asians), the incidence of HBV is not as much a concern as the incidence of HCV, which assumes a bigger role in the etiology of liver cancer (40). For the latter group, the patterns among immigrants are consistent and gender specific, with a higher incidence and mortality for males when coming to the U.S., but females having stabilized or slightly decreased rates. This has been shown for different populations (Hispanics and non-Hispanic Blacks) (41-43). CDC’s National Comprehensive Cancer Control Program (NCCCCP) is currently working on the development and implementation of an action plan that would facilitate greater implementation and uptake of strategies and interventions to address liver cancer within selected pilot programs that have a high liver cancer

1
2
3 burden. The action plan will contain interventions specific to increasing support for vaccine-
4 based strategies to eliminate HBV transmission, and development of prevention and health
5 services that include screening for HBV and HCV infections linked to appropriate medical
6 management and care (in alignment with recommendations), community education about HBV
7 and HCV, and the improvement of viral hepatitis surveillance. Improved surveillance for HBV
8 and patients with HCV-related cirrhosis has the potential to result in the detection of more
9 cancers at a localized stage when surgery may be possible and more beneficial (44).
10
11
12
13
14
15
16
17
18
19
20
21

22 ***Strength and Limitations***

23
24 This analysis has several strengths, including that it includes a very large number of US states,
25 making it the most geographically-comprehensive survival study to our knowledge. Also, the
26 sophisticated and complex methodology takes into account the competing risks of death that are
27 higher for elderly than for younger cancer patients. Finally, more than 70% of all cases included
28 in this analysis were morphologically verified, contributing to the high quality of the data used.
29
30 A limitation of our analysis is that some stage and race categories had missing data or small
31 numbers. The small black population in some states precluded the construction of life tables for
32 the black population in these states; therefore the state-specific life tables for all races combined
33 were used instead. Additionally, data on populations with a higher burden of liver cancer,
34 including Asian/Pacific Islanders and Hispanics, were not collected or analyzed in this study.
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50

51 ***Conclusions***

52
53 Cancer incidence in the United States is expected to increase greatly due to demographic changes
54 such as an aging population and a larger proportion of individuals from racial/ethnic groups; it is
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

estimated that liver cancer will rank the second highest of increase (59%) between 2010 through 2030 among all cancer sites (45). This analysis suggests some progress in five-year survival for liver cancer in the U.S.; however, there is still much more work that needs to be done in order to reduce the burden of this cancer. Improvements in surveillance, prevention and detection of HBV and HCV infection may have the greatest potential of leading to earlier detection resulting in increased survival.

Figures and Tables

Figure 1. Liver cancer: 5-year age-standardized net survival (%) for adults (15-99 years) diagnosed during 2001-2003 and 2004-2009, and absolute change (%): states grouped by U.S. Census Region.

Note: Data from 37 statewide cancer registries (covering 80.6% of the population) are ranked within U.S. Census Region by the survival estimate for 2004-2009. Dark colors denote states affiliated with the National Program of Cancer Registries (NPCR); pale colors denote states affiliated with the Surveillance, Epidemiology and End Results (SEER) Program; * denotes states affiliated with both federal surveillance programs. Change (%) not plotted if a survival estimate was not available for one calendar period or one or more estimates was not age-standardized.

Figure 2. Liver cancer: 5-year age-standardized net survival (%) for adults (15-99 years), by state, race and calendar period of diagnosis.

Note: the pooled (US) survival estimate for each calendar period is shown by the horizontal (solid) line with corresponding 95.0% and 99.8% control limits (dotted lines).

Supplemental Table 1. Liver cancer: number of cases for adults (15-99 years) diagnosed during 2001-2003 and 2004-2009 and distribution (%) by SEER Summary Stage 2000 at diagnosis, race and calendar period of diagnosis.

Note: NPCR indicates National Program of Cancer Registries; SEER indicates Surveillance, Epidemiology, and End Results program. Information on stage was not available for two states (Maryland and Wisconsin), or for Rhode Island for cases diagnosed during 2004- 2009. This is the same information that appears in Table 1.

Supplemental Table 2. Liver cancer: 1-, 3- and 5-years age-standardized net survival (%) for adults (15-99 years) diagnosed during 2001-2003 and 2004-2009, by race and calendar period of diagnosis.

Note: NPCR indicates National Program of Cancer Registries; SEER indicates Surveillance, Epidemiology, and End Results program. Unstandardized estimates are italicized.

1
2
3 Supplemental Table 3. Liver cancer: 5-year age-standardized net survival (%) for adults (15-99
4 years) diagnosed during 2001-2003 and 2004-2009, by SEER Summary Stage 2000 at
5 diagnosis, race and calendar period.
6
7

8 Note: NPCR indicates National Program of Cancer Registries; SEER indicates Surveillance,
9 Epidemiology, and End Results program. Information on stage was not available for two states
10 (Maryland and Wisconsin), or for Rhode Island for cases diagnosed during 2004- 2009.
11
12
13
14

15 Unstandardized estimates are italicized.
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 1. Liver cancer: number of cases for males and females (15-99 years) diagnosed 2001-2009 and distribution (%) by SEER Summary Stage 2000 (SS2000) at diagnosis, by race and calendar period of diagnosis.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

| SS2000 | 2001-2003 | | | 2004-2009 | | |
|-----------------|-----------|--------|-------|-----------|--------|--------|
| | All races | White | Black | All races | White | Black |
| No. of patients | 33,690 | 25,500 | 4,225 | 92,571 | 69,374 | 13,002 |
| Localized (%) | 33.4 | 33.2 | 30.4 | 41.0 | 40.9 | 38.8 |
| Regional (%) | 22.4 | 21.6 | 23.6 | 24.4 | 23.8 | 25.9 |
| Distant (%) | 18.4 | 18.2 | 20.4 | 17.6 | 17.4 | 19.8 |
| Unknown (%) | 25.8 | 27.0 | 25.6 | 17.0 | 17.8 | 15.5 |

Table 2. Liver cancer: age-standardized net survival (%) at 1-, 3- and 5-years for females (15-99 years) diagnosed 2001-2009, by race and calendar period of diagnosis.

| Years | 2001-2003 | | | | | | 2004-2009 | | | | | |
|-------|-----------|-------------|--------|-------------|--------|-------------|-----------|-------------|--------|-------------|--------|-------------|
| | All races | | White | | Black | | All races | | White | | Black | |
| | NS (%) | 95% CI | NS (%) | 95% CI | NS (%) | 95% CI | NS (%) | 95% CI | NS (%) | 95% CI | NS (%) | 95% CI |
| 1 | 31.8 | 31.3 - 32.3 | 31.7 | 31.1 - 32.3 | 27.3 | 25.8 - 28.9 | 38.2 | 37.5 - 38.5 | 38.0 | 37.6 - 38.4 | 32.9 | 31.9 - 33.9 |
| 3 | 16.2 | 15.8 - 16.7 | 15.7 | 15.3 - 16.2 | 13.2 | 11.9 - 14.4 | 20.5 | 20.1 - 20.8 | 19.9 | 19.5 - 20.3 | 16.5 | 15.5 - 17.5 |
| 5 | 12.2 | 11.8 - 12.6 | 11.7 | 11.3 - 12.1 | 9.1 | 8.0 - 10.2 | 14.8 | 14.4 - 15.2 | 14.3 | 13.8 - 14.8 | 11.4 | 10.3 - 12.5 |

Table 3. Liver cancer: 5-year age-standardized net survival (%) for females (15-99 years) diagnosed 2001-2009, by SEER Summary Stage (SS2000) at diagnosis, race and calendar period of diagnosis.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

| | 2001-2003 | | | | | | | | | | | 2004-2009 | | | | | | | | | | | | | |
|------------|-----------|----|---|------|--------|----|---|------|-------|----|---|-----------|----|----|---|-------|----|----|---|-------|----|----|--------|----|--|
| | All races | | | | White | | | | Black | | | All races | | | | White | | | | Black | | | | | |
| | N | | | | NS (%) | | | | N | | | NS (%) | | | | N | | | | N | | | NS (%) | | |
| All stages | 12 | 11 | - | 12.5 | 11.7 | 11 | - | 12.1 | 9 | 8 | - | 10.2 | 14 | 14 | - | 15.2 | 14 | 13 | - | 14 | 11 | 10 | - | 12 | |
| Localized | 22 | 22 | - | 23.8 | 22.4 | 21 | - | 23.4 | 15 | 13 | - | 18.2 | 25 | 24 | - | 26.5 | 24 | 23 | - | 25 | 20 | 18 | - | 23 | |
| Regional | 8 | 7 | - | 9.0 | 7.6 | 6 | - | 8.4 | 8 | 6 | - | 10.4 | 9 | 8 | - | 10.2 | 9 | 8 | - | 9 | 7 | 5 | - | 8 | |
| Distant | 2 | 2 | - | 3.3 | 2.4 | 2 | - | 2.9 | 2 | 1 | - | 3.8 | 3 | 3 | - | 4.0 | 2 | 2 | - | 3 | 3 | 2 | - | 5 | |
| Unknown | 8 | 7 | - | 8.9 | 7.9 | 7 | - | 8.7 | 7 | 5 | - | 8.8 | 8 | 8 | - | 9.6 | 9 | 8 | - | 9 | 6 | 4 | - | 7 | |
| Unknown | 2 | 6 | - | | | 2 | - | | 0 | 3 | - | | 2 | 2 | - | | 0 | 1 | - | 8 | 2 | 6 | - | 8 | |

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

References:

1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. *Int J Cancer*. 2015;136(5):E359-86. doi: 10.1002/ijc.29210. Epub 2014 Oct 9.
2. Okuda K, Fujimoto I, Hanai A, Urano Y. Changing incidence of hepatocellular carcinoma in Japan. *Cancer Res* 1987;47:4967–4972. S300 E. JENNY HEATHCOTE GASTROENTEROLOGY Vol. 127, No. 5
3. Taylor-Robinson SD, Foster GR, Arora S, Gargreaves S, Thomas HC. Increase in primary liver cancer in the UK 1979-1994. *Lancet* 1997;350:1142–1143.
4. Deuffic S, Poynard T, Buffat L, Valleron AJ. Trends in primary liver cancer. *Lancet* 1998;351:214–215.
5. El-Serag HB, Davila JA, Petersen NJ, McGlynn KA. The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update. *Ann Intern Med* 2003;139:817–823.
6. Weir, H. K., Thompson, T. D., Soman, A., Møller, B. and Leadbetter, S. (2015), The past, present, and future of cancer incidence in the United States: 1975 through 2020. *Cancer*, 121: 1827–1837. doi:10.1002/cncr.29258.
7. U.S. Cancer Statistics Working Group. United States Cancer Statistics: 1999–2013 Incidence and Mortality Web-based Report. Atlanta: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute; 2016. Available at: www.cdc.gov/uscs, accessed February 3, 2017. <http://www.cdc.gov/cancer/liver/index.htm>
8. Ryerson AB, Ehemann CR, Altekruse SF, Ward JW, Jemal A, Sherman RL, et al. Annual report to the nation on the status of cancer, 1975–2012, featuring the increasing incidence of liver cancer. *Cancer* 2016;122(9):1312–37.
9. Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. *J Hepatol* 2006;45:529--38.
10. Welzel TM, Graubard BI, Quraishi S, Zeuzem S, Davila JA, El-Serag HB, et al. Population attributable fractions of risk factors for hepatocellular carcinoma in the United States. *Am J Gastroenterol*. 2013;108(8):1314-21. doi: 10.1038/ajg.2013.160. Epub 2013 Jun 11.
11. Gretten TF, Papendorf F, Bleck JS, et al. Survival rate in patients with hepatocellular carcinoma: a retrospective analysis of 389 patients. *British Journal of Cancer*. 2005;92(10):1862-1868. doi:10.1038/sj.bjc.6602590.


- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
12. Allemani C, Weir HK, Carreira H, et al. Global surveillance of cancer survival 1995-2009: analysis of individual data for 25,676,887 patients from 279 population-based registries in 67 countries (CONCORD-2). *Lancet*. 2015;385(9972):977-1010. SEER 2007 Multiple Primary and Histology Coding Rules. <http://seer.cancer.gov/tools/mphrules/>.
 13. Fritz AG, Percy C, Jack A, Shanmugaratnam K, Sobin LH, Parkin DM, Whelan SL, eds. International Classification of Diseases for Oncology (ICD-O). 3rd edn. Geneva: World Health Organization; 2000.
 14. Young JL, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA. SEER Summary Staging Manual - 2000: Codes and Coding Instructions. NIH Pub. No. 01-4969. Bethesda, MD: National Cancer Institute; 2001.
 15. Surveillance Epidemiology and End Results program. Collaborative Stage. Bethesda, MD: National Cancer Institute, 2004. <http://seer.cancer.gov/tools/collabstaging/> (accessed 1 April 2016).
 16. Pohar Perme M, Stare J, Estève J. On estimation in relative survival. *Biometrics* 2012; 68: 113-20.
 17. Spika D, Rachet B, Bannon F, Woods LM, Maringe C, Bonaventure A, Coleman MP, Allemani C. Life tables for the CONCORD-2 study. London: CONCORD Central Analytic Team, 2015. <http://csg.lshtm.ac.uk/tools-analysis/life-tables/> (accessed 1 April 2016).
 18. Rachet B, Maringe C, Woods LM, Ellis L, Spika D, Allemani C. Multivariable flexible modelling for estimating complete, smoothed life tables for sub-national populations. *BMC Public Health* 2015; 15.
 19. Corazziari I, Quinn MJ, Capocaccia R. Standard cancer patient population for age standardising survival ratios. *Eur J Cancer* 2004; 40: 2307-16.
 20. Quaresma M, Coleman MP, Rachet B. Funnel plots for population-based cancer survival: principles, methods and applications. *Stat Med* 2014; 33: 1070-80.
 21. Allemani C, Harewood R, Johnson C, et al. Population-based cancer survival in the US: data, quality control and statistical methods. *Cancer*. 2017.
 22. Micheli A, Ciampichinia R, Oberaigner W, et. al. The EURO CARE Working Group. European Journal of Cancer. The advantage of women in cancer survival: An analysis of EURO CARE-4 data A.
 23. Bruix J, Sherman M; American Association for the Study of Liver Diseases: Management of hepatocellular carcinoma: an update. *Hepatology* 53 (3): 1020-2, 2011. [PUBMED Abstract]

- 1
2
3
4
5 24. Siegel AB¹, McBride RB, El-Serag HB, Hershman DL, Brown RS Jr, Renz JF, Emond J,
6 Neugut AI. Racial disparities in utilization of liver transplantation for hepatocellular
7 carcinoma in the United States, 1998-2002. *Am J Gastroenterol*. 2008 Jan;103(1):120-7.
8 Epub 2007 Nov 15.
9
10
11
12 25. Reid AE¹, Resnick M, Chang Y, Buerstatte N, Weissman JS. Disparity in use of orthotopic
13 liver transplantation among blacks and whites. *Liver Transpl*. 2004 Jul;10(7):834-41.
14
15
16 26. Artinyan A¹, Mailey B, Sanchez-Luege N, Khalili J, Sun CL, Bhatia S, Wagman LD, Nissen
17 N, Colquhoun SD, Kim J. Race, ethnicity, and socioeconomic status influence the survival of
18 patients with hepatocellular carcinoma in the United States. *Cancer*. 2010 Mar 1;116(5):1367-77.
19 doi: 10.1002/cncr.24817.
20
21
22 27. Carey LA, Perou CM, Livasy CA, et al. Race, Breast Cancer Subtypes, and Survival in the
23 Carolina Breast Cancer Study. *JAMA*. 2006;295(21):2492-2502. doi:10.1001/jama.295.21.2492.
24
25
26 28. Kubo S, Hirohashi K, Tanaka H, Tsukamoto T, Shuto T, Ikebe T, Yamamoto T, Wakasa K,
27 Nishiguchi S, Kuroki T, Kinoshita H. Risk factors for recurrence after resection of hepatitis C
28 virus-related hepatocellular carcinoma. *World J Surg*. 2000 Dec;24(12):1559-65.
29
30
31
32
33 29. Kubo S¹, Hirohashi K, Tanaka H, Tsukamoto T, Shuto T, Yamamoto T, Ikebe T, Wakasa K,
34 Nishiguchi S, Kinoshita H. Effect of viral status on recurrence after liver resection for patients
35 with hepatitis B virus-related hepatocellular carcinoma. *Cancer*. 2000 Mar 1;88(5):1016-24.
36
37
38
39 30. Wu JC¹, Huang YH, Chau GY, Su CW, Lai CR, Lee PC, Huo TI, Sheen IJ, Lee SD, Lui
40 WY. Risk factors for early and late recurrence in hepatitis B-related hepatocellular carcinoma. *J*
41 *Hepatol*. 2009 Nov;51(5):890-7. doi: 10.1016/j.jhep.2009.07.009. Epub 2009 Jul 23.
42
43
44 31. Kubo S¹, Takemura S, Sakata C, Urata Y, Uenishi T. Adjuvant therapy after curative
45 resection for hepatocellular carcinoma associated with hepatitis virus. *Liver Cancer*. 2013
46 Jan;2(1):40-6. doi: 10.1159/000346214.
47
48
49 32. Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ. The
50 prevalence of hepatitis C virus infection in the United States, 1999 through 2002. *Ann Intern*
51 *Med*. 2006;144(10):705-14.
52
53
54 33. Daniels D, Grytdal S, Wasley A. Surveillance for acute viral hepatitis - United States, 2007.
55 *MMWR Surveill Summ*. 2009;58(3):1-27.
56
57
58
59
60

- 1
2
3 34. Chhatwal J, Kanwal F, Roberts MS, Dunn MA. Cost-effectiveness and budget impact of
4 hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States. *Ann Intern Med.*
5 2015;162(6):397-406. doi: 10.7326/M14-1336.
6
7
8 35. Lok, Anna Suk-Fong. Does antiviral therapy for hepatitis B and C prevent hepatocellular
9 carcinoma? *Journal of Gastroenterology and Hepatology*
10
11 36. Smith BD, Morgan RL, Beckett GA, Falck-Ytter Y, Holtzman D, Teo CG, et al.
12 Recommendations for the identification of chronic hepatitis C virus infection among persons
13 born during 1945-1965. *MMWR Recomm Rep.* 2012;61(RR-4):1-32.
14
15
16
17 37. Moyer VA. Screening for hepatitis C virus infection in adults: U.S. Preventive Services Task
18 Force recommendation statement. *Ann Intern Med.* 2013;159(5):349-57. doi: 10.7326/0003-
19 4819-159-5-201309030-00672.
20
21
22 38. IOM (Institute of Medicine). 2010. *Hepatitis and Liver Cancer: A National Strategy for*
23 *Prevention and Control of Hepatitis B and C.* Washington, DC: The National Academies Press.
24
25
26
27 39. Moore MS, Ivanina E, Bornschlegel K, Qiao B, Schymura MJ, Laraque F.
28 Hepatocellular Carcinoma and Viral Hepatitis in New York City. *Clinical Infectious Diseases.* 2016:ciw605.
29
30
31 40. El-Serag HB, Lau M, Eschbach K, Davila J, Goodwin J. Epidemiology of hepatocellular carcinoma in
32 Hispanics in the United States. *Arch Intern Med.*
33 2007;167(18):1983-9.
34
35
36 41. Pinheiro PS, Sherman RL, Trapido EJ, Fleming LE, Huang Y, Gomez-Marin O, et al. Cancer incidence in
37 first generation U.S. Hispanics: Cubans, Mexicans, Puerto Ricans, and new Latinos. *Cancer Epidemiol*
38 *Biomarkers Prev.* 2009 Aug;18(8):2162-9.
39
40
41
42 42. Pinheiro PS, Callahan KE, Siegel RL, Jin H, Morris CR, Trapido EJ, et al.
43 Cancer Mortality in Hispanic Ethnic Groups. *Cancer Epidemiol Biomarkers Prev.* 2017 Mar;26(3):376-82.
44
45
46 43. Pinheiro PS, Callahan KE, Ragin CR, Hage RW, Hylton T, Kobetz EN. Black heterogeneity in cancer
47 mortality: US-Blacks, Haitians, and Jamaicans.
48 *Cancer Control.* 2016;23(4):347.
49
50
51 44. El-Serag HB, Davila JA. Surveillance for hepatocellular carcinoma: in whom and how?
52 Editorial. *Ther Adv Gastroenterol.* 2011;4 (1):5-10. DOI: 10.1177/1756283X10385964
53
54
55 45. Smith BD1, Smith GL, Hurria A, Hortobagyi GN, Buchholz TA. Future of cancer incidence
56 in the United States: burdens upon an aging, changing nation. *J Clin Oncol.* 2009 Jun
57 10;27(17):2758-65. doi: 10.1200/JCO.2008.20.8983. Epub 2009 Apr 29.
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 2

86x60mm (600 x 600 DPI)

| Stage | 2001-2003 | | | 2004-2009 | | | |
|------------------------|-----------------|--------|-------|-----------|--------|--------|-------|
| | All races | White | Black | All races | White | Black | |
| UNITED STATES | | | | | | | |
| No. of patients | 33,690 | 25,500 | 4,225 | 92,571 | 69,374 | 13,002 | |
| Localized (%) | 33.4 | 33.2 | 30.4 | 41.0 | 40.9 | 38.8 | |
| Regional (%) | 22.4 | 21.6 | 23.6 | 24.4 | 23.8 | 25.9 | |
| Distant (%) | 18.4 | 18.2 | 20.4 | 17.6 | 17.4 | 19.8 | |
| Unknown (%) | 25.8 | 27.0 | 25.6 | 17.0 | 17.8 | 15.5 | |
| NORTHEAST | | | | | | | |
| New England | | | | | | | |
| Connecticut (SEER) | No. of patients | 492 | 421 | 53 | 1,411 | 1,170 | 164 |
| | Localized (%) | 36.6 | 36.8 | 35.8 | 41.2 | 40.8 | 42.1 |
| | Regional (%) | 17.5 | 16.6 | 22.6 | 24.9 | 23.9 | 32.3 |
| | Distant (%) | 19.5 | 19.5 | 17.0 | 18.9 | 19.4 | 15.9 |
| | Unknown (%) | 26.4 | 27.1 | 24.5 | 15.0 | 15.9 | 9.8 |
| Massachusetts (NPCR) | No. of patients | 998 | 827 | 75 | 2,741 | 2,299 | 178 |
| | Localized (%) | 34.4 | 34.0 | 28.0 | 40.9 | 41.0 | 33.7 |
| | Regional (%) | 25.4 | 24.9 | 32.0 | 26.4 | 26.1 | 32.6 |
| | Distant (%) | 15.8 | 16.2 | 14.7 | 16.7 | 16.8 | 15.7 |
| | Unknown (%) | 24.4 | 24.9 | 25.3 | 16.0 | 16.1 | 18.0 |
| New Hampshire (NPCR) | No. of patients | 133 | 118 | - | 355 | 332 | - |
| | Localized (%) | 24.8 | 24.6 | 66.7 | 35.5 | 35.5 | 50.0 |
| | Regional (%) | 24.1 | 21.2 | 33.3 | 27.9 | 28.6 | 50.0 |
| | Distant (%) | 16.5 | 17.8 | 0.0 | 17.2 | 17.8 | 0.0 |
| | Unknown (%) | 34.6 | 36.4 | 0.0 | 19.4 | 18.1 | 0.0 |
| Rhode Island (NPCR) | No. of patients | 176 | 161 | 10 | 409 | 353 | 32 |
| | Localized (%) | 29.5 | 29.8 | 30.0 | - | - | - |
| | Regional (%) | 29.0 | 28.6 | 40.0 | - | - | - |
| | Distant (%) | 15.3 | 13.7 | 30.0 | - | - | - |
| | Unknown (%) | 26.1 | 28.0 | 0.0 | - | - | - |
| Mid Atlantic | | | | | | | |
| New Jersey (NPCR/SEER) | No. of patients | 1,421 | 1,093 | 199 | 3,339 | 2,587 | 488 |
| | Localized (%) | 30.6 | 29.1 | 33.2 | 41.6 | 41.0 | 40.8 |
| | Regional (%) | 19.7 | 19.7 | 21.1 | 21.2 | 21.3 | 20.7 |
| | Distant (%) | 20.1 | 20.4 | 21.6 | 16.4 | 16.2 | 18.0 |
| | Unknown (%) | 29.6 | 30.8 | 24.1 | 20.8 | 21.5 | 20.5 |
| New York (NPCR) | No. of patients | 3,465 | 2,458 | 578 | 8,877 | 6,052 | 1,670 |
| | Localized (%) | 28.1 | 27.8 | 23.9 | 41.4 | 40.4 | 39.2 |
| | Regional (%) | 21.0 | 20.5 | 24.2 | 23.9 | 24.0 | 25.5 |
| | Distant (%) | 17.7 | 17.4 | 19.7 | 18.6 | 18.7 | 21.0 |
| | Unknown (%) | 33.2 | 34.3 | 32.2 | 16.1 | 16.9 | 14.4 |
| Pennsylvania (NPCR) | No. of patients | 2,004 | 1,569 | 322 | 5,026 | 3,957 | 821 |
| | Localized (%) | 31.2 | 31.2 | 29.2 | 42.6 | 41.7 | 43.7 |
| | Regional (%) | 24.5 | 25.7 | 20.8 | 26.5 | 26.3 | 28.7 |
| | Distant (%) | 20.5 | 20.0 | 23.6 | 18.2 | 18.7 | 16.9 |
| | Unknown (%) | 23.8 | 23.0 | 26.4 | 12.8 | 13.3 | 10.6 |
| SOUTH | | | | | | | |
| South Atlantic | | | | | | | |
| Delaware (NPCR) | No. of patients | 106 | 87 | 16 | 310 | 218 | 81 |
| | Localized (%) | 41.5 | 41.4 | 43.8 | 45.8 | 47.2 | 40.7 |
| | Regional (%) | 21.7 | 17.2 | 43.8 | 26.1 | 25.7 | 27.2 |
| | Distant (%) | 16.0 | 17.2 | 12.5 | 19.7 | 19.3 | 22.2 |
| | Unknown (%) | 20.8 | 24.1 | 0.0 | 8.4 | 7.8 | 9.9 |
| Florida (NPCR) | No. of patients | 2,721 | 2,337 | 276 | 7,339 | 6,063 | 946 |
| | Localized (%) | 29.1 | 29.3 | 26.4 | 38.9 | 39.6 | 33.4 |
| | Regional (%) | 19.8 | 19.3 | 25.4 | 23.3 | 23.0 | 26.6 |
| | Distant (%) | 20.3 | 20.1 | 22.8 | 16.5 | 16.0 | 20.0 |
| | Unknown (%) | 30.8 | 31.4 | 25.4 | 21.3 | 21.3 | 20.0 |
| Georgia (NPCR/SEER) | No. of patients | 813 | 540 | 217 | 2,698 | 1,798 | 764 |
| | Localized (%) | 35.9 | 36.3 | 33.6 | 43.7 | 44.4 | 42.3 |
| | Regional (%) | 21.5 | 20.4 | 24.0 | 25.8 | 25.0 | 27.7 |
| | Distant (%) | 19.8 | 20.6 | 19.4 | 18.9 | 17.7 | 21.9 |
| | Unknown (%) | 22.8 | 22.8 | 23.0 | 11.6 | 12.9 | 8.1 |

Cancer

| Stage | 2001-2003 | | | 2004-2009 | | | |
|---------------------------|-----------------|-------|-------|-----------|--------|-------|-------|
| | All races | White | Black | All races | White | Black | |
| Maryland (NPCR) | No. of patients | 657 | 411 | 192 | 1,524 | 901 | 517 |
| | Localized (%) | - | - | - | - | - | - |
| | Regional (%) | - | - | - | - | - | - |
| | Distant (%) | - | - | - | - | - | - |
| | Unknown (%) | - | - | - | - | - | - |
| North Carolina (NPCR) | No. of patients | 934 | 695 | 197 | 2,873 | 2,094 | 631 |
| | Localized (%) | 38.1 | 41.3 | 28.9 | 41.8 | 41.8 | 40.9 |
| | Regional (%) | 21.1 | 20.4 | 21.8 | 25.5 | 25.6 | 26.0 |
| | Distant (%) | 17.8 | 16.3 | 21.8 | 17.9 | 17.3 | 18.9 |
| | Unknown (%) | 23.0 | 22.0 | 27.4 | 14.8 | 15.3 | 14.3 |
| South Carolina (NPCR) | No. of patients | 485 | 352 | 118 | 1,339 | 951 | 347 |
| | Localized (%) | 36.9 | 38.9 | 30.5 | 40.0 | 40.9 | 37.5 |
| | Regional (%) | 17.5 | 18.2 | 16.1 | 22.3 | 22.0 | 23.1 |
| | Distant (%) | 15.5 | 15.1 | 16.1 | 17.8 | 17.4 | 19.9 |
| | Unknown (%) | 30.1 | 27.8 | 37.3 | 19.9 | 19.8 | 19.6 |
| West Virginia (NPCR) | No. of patients | 230 | 220 | - | 562 | 531 | 27 |
| | Localized (%) | 25.7 | 25.9 | 25.0 | 35.6 | 35.6 | 33.3 |
| | Regional (%) | 16.1 | 16.4 | 0.0 | 21.4 | 21.7 | 14.8 |
| | Distant (%) | 19.1 | 19.1 | 12.5 | 15.1 | 14.5 | 29.6 |
| | Unknown (%) | 39.1 | 38.6 | 62.5 | 27.9 | 28.2 | 22.2 |
| East South Central | | | | | | | |
| Alabama (NPCR) | No. of patients | 514 | 381 | 119 | 1,408 | 1,068 | 317 |
| | Localized (%) | 30.2 | 29.7 | 30.3 | 43.4 | 44.7 | 38.8 |
| | Regional (%) | 21.6 | 21.5 | 20.2 | 20.7 | 19.9 | 23.7 |
| | Distant (%) | 18.7 | 19.7 | 16.8 | 17.0 | 16.0 | 19.9 |
| | Unknown (%) | 29.6 | 29.1 | 32.8 | 18.8 | 19.4 | 17.7 |
| Kentucky (NPCR/SEER) | No. of patients | 466 | 418 | 41 | 1,353 | 1,207 | 129 |
| | Localized (%) | 35.8 | 35.4 | 36.6 | 43.7 | 42.8 | 50.4 |
| | Regional (%) | 21.2 | 20.6 | 31.7 | 23.7 | 24.3 | 17.8 |
| | Distant (%) | 17.2 | 17.7 | 14.6 | 18.6 | 17.9 | 24.8 |
| | Unknown (%) | 25.8 | 26.3 | 17.1 | 14.1 | 15.0 | 7.0 |
| Mississippi (NPCR) | No. of patients | 128 | 91 | 28 | 899 | 622 | 251 |
| | Localized (%) | 35.9 | 37.4 | 35.7 | 38.2 | 41.0 | 32.3 |
| | Regional (%) | 20.3 | 19.8 | 14.3 | 29.0 | 26.5 | 34.3 |
| | Distant (%) | 22.7 | 24.2 | 21.4 | 20.2 | 19.3 | 21.9 |
| | Unknown (%) | 21.1 | 18.7 | 28.6 | 12.6 | 13.2 | 11.6 |
| Tennessee (NPCR) | No. of patients | 177 | 149 | 22 | 1,805 | 1,417 | 334 |
| | Localized (%) | 40.7 | 42.3 | 36.4 | 46.1 | 46.4 | 42.8 |
| | Regional (%) | 22.6 | 24.2 | 9.1 | 22.7 | 22.4 | 23.1 |
| | Distant (%) | 19.2 | 16.1 | 36.4 | 16.8 | 16.7 | 19.8 |
| | Unknown (%) | 17.5 | 17.4 | 18.2 | 14.4 | 14.5 | 14.4 |
| West South Central | | | | | | | |
| Louisiana (NPCR/SEER) | No. of patients | 694 | 464 | 211 | 1,739 | 1,066 | 609 |
| | Localized (%) | 41.2 | 43.8 | 37.0 | 49.7 | 50.3 | 47.5 |
| | Regional (%) | 24.9 | 24.6 | 25.1 | 23.1 | 22.1 | 25.0 |
| | Distant (%) | 18.0 | 15.5 | 22.7 | 18.0 | 17.4 | 19.2 |
| | Unknown (%) | 15.9 | 16.2 | 15.2 | 9.3 | 10.2 | 8.4 |
| Oklahoma (NPCR) | No. of patients | 425 | 319 | 37 | 1,280 | 979 | 85 |
| | Localized (%) | 28.7 | 28.5 | 18.9 | 37.3 | 39.0 | 31.8 |
| | Regional (%) | 15.3 | 14.4 | 16.2 | 20.0 | 19.0 | 24.7 |
| | Distant (%) | 21.9 | 23.2 | 24.3 | 19.8 | 19.1 | 24.7 |
| | Unknown (%) | 34.1 | 33.9 | 40.5 | 23.0 | 22.9 | 18.8 |
| Texas (NPCR) | No. of patients | 3,543 | 2,944 | 405 | 10,265 | 8,253 | 1,422 |
| | Localized (%) | 34.1 | 34.2 | 33.1 | 41.5 | 42.7 | 35.6 |
| | Regional (%) | 17.3 | 16.5 | 22.2 | 20.7 | 19.7 | 26.1 |
| | Distant (%) | 17.6 | 17.4 | 20.0 | 17.2 | 16.7 | 19.9 |
| | Unknown (%) | 31.0 | 31.8 | 24.7 | 20.6 | 20.9 | 18.4 |

| Stage | | 2001-2003 | | | 2004-2009 | | |
|---------------------------|-----------------|-----------|-------|-------|-----------|-------|-------|
| | | All races | White | Black | All races | White | Black |
| MIDWEST | | | | | | | |
| East North Central | | | | | | | |
| Michigan (NPCR/SEER) | No. of patients | 1,412 | 1,072 | 278 | 3,485 | 2,559 | 755 |
| | Localized (%) | 30.5 | 30.1 | 31.3 | 35.0 | 35.0 | 34.8 |
| | Regional (%) | 19.6 | 18.9 | 21.9 | 16.2 | 16.1 | 15.8 |
| | Distant (%) | 20.0 | 19.1 | 24.8 | 19.3 | 18.8 | 21.5 |
| | Unknown (%) | 30.0 | 31.8 | 21.9 | 29.5 | 30.1 | 27.9 |
| Ohio (NPCR) | No. of patients | 1,301 | 1,036 | 215 | 3,476 | 2,735 | 634 |
| | Localized (%) | 28.5 | 29.0 | 26.5 | 35.5 | 34.8 | 36.1 |
| | Regional (%) | 17.8 | 18.0 | 17.2 | 21.9 | 20.7 | 26.7 |
| | Distant (%) | 15.5 | 15.6 | 14.9 | 15.0 | 15.1 | 14.8 |
| | Unknown (%) | 38.1 | 37.5 | 41.4 | 27.6 | 29.4 | 22.4 |
| Wisconsin (NPCR) | No. of patients | 660 | 587 | 45 | 1,661 | 1,370 | 158 |
| | Localized (%) | - | - | - | - | - | - |
| | Regional (%) | - | - | - | - | - | - |
| | Distant (%) | - | - | - | - | - | - |
| | Unknown (%) | - | - | - | - | - | - |
| West North Central | | | | | | | |
| Iowa (SEER) | No. of patients | 295 | 276 | - | 861 | 795 | 28 |
| | Localized (%) | 30.2 | 30.1 | 40.0 | 36.4 | 37.0 | 32.1 |
| | Regional (%) | 28.8 | 29.7 | 20.0 | 30.0 | 29.1 | 42.9 |
| | Distant (%) | 20.3 | 19.9 | 20.0 | 20.6 | 20.0 | 25.0 |
| | Unknown (%) | 20.7 | 20.3 | 20.0 | 13.1 | 14.0 | 0.0 |
| Nebraska (NPCR) | No. of patients | 243 | 217 | 11 | 595 | 513 | 44 |
| | Localized (%) | 33.3 | 32.7 | 54.5 | 34.6 | 35.3 | 29.5 |
| | Regional (%) | 22.2 | 21.7 | 18.2 | 31.1 | 31.0 | 31.8 |
| | Distant (%) | 15.6 | 14.7 | 18.2 | 17.8 | 16.6 | 25.0 |
| | Unknown (%) | 28.8 | 30.9 | 9.1 | 16.5 | 17.2 | 13.6 |
| WEST | | | | | | | |
| Mountain | | | | | | | |
| Colorado (NPCR) | No. of patients | 521 | 436 | 32 | 1,442 | 1,255 | 74 |
| | Localized (%) | 37.0 | 37.8 | 25.0 | 41.9 | 41.5 | 33.8 |
| | Regional (%) | 21.9 | 20.9 | 34.4 | 25.0 | 24.5 | 27.0 |
| | Distant (%) | 20.2 | 19.5 | 25.0 | 19.2 | 19.7 | 25.7 |
| | Unknown (%) | 20.9 | 21.8 | 15.6 | 13.9 | 14.3 | 13.5 |
| Idaho (NPCR) | No. of patients | 92 | 88 | - | 332 | 316 | - |
| | Localized (%) | 33.7 | 33.0 | - | 38.0 | 38.0 | - |
| | Regional (%) | 29.3 | 30.7 | - | 26.2 | 26.9 | - |
| | Distant (%) | 18.5 | 17.0 | - | 21.1 | 21.5 | - |
| | Unknown (%) | 18.5 | 19.3 | - | 14.8 | 13.6 | - |
| Montana (NPCR) | No. of patients | 76 | 67 | - | 232 | 191 | - |
| | Localized (%) | 25.0 | 23.9 | 100.0 | 40.5 | 42.4 | - |
| | Regional (%) | 23.7 | 23.9 | 0.0 | 31.5 | 29.8 | - |
| | Distant (%) | 10.5 | 11.9 | 0.0 | 17.2 | 17.8 | - |
| | Unknown (%) | 40.8 | 40.3 | 0.0 | 10.8 | 9.9 | - |
| New Mexico (SEER) | No. of patients | 332 | 293 | - | 911 | 783 | 13 |
| | Localized (%) | 42.8 | 43.3 | 33.3 | 42.7 | 42.5 | 38.5 |
| | Regional (%) | 16.3 | 14.7 | 0.0 | 16.9 | 17.2 | 15.4 |
| | Distant (%) | 19.3 | 19.8 | 33.3 | 18.8 | 19.2 | 30.8 |
| | Unknown (%) | 21.7 | 22.2 | 33.3 | 21.6 | 21.1 | 15.4 |
| Utah (SEER) | No. of patients | 139 | 117 | - | 456 | 405 | 11 |
| | Localized (%) | 46.0 | 46.2 | - | 44.5 | 45.4 | 45.5 |
| | Regional (%) | 24.5 | 21.4 | - | 30.9 | 30.1 | 18.2 |
| | Distant (%) | 15.1 | 17.1 | - | 14.5 | 14.3 | 18.2 |
| | Unknown (%) | 14.4 | 15.4 | - | 10.1 | 10.1 | 18.2 |
| Wyoming (NPCR) | No. of patients | 41 | 38 | - | 131 | 125 | - |
| | Localized (%) | 17.1 | 18.4 | 0.0 | 43.5 | 44.0 | - |
| | Regional (%) | 17.1 | 18.4 | 0.0 | 22.9 | 23.2 | - |
| | Distant (%) | 14.6 | 15.8 | 0.0 | 13.7 | 12.8 | - |
| | Unknown (%) | 51.2 | 47.4 | 100.0 | 19.8 | 20.0 | - |

Cancer

| Stage | 2001-2003 | | | 2004-2009 | | | |
|---------------------------|-----------------|-------|-------|-----------|--------|--------|-------|
| | All races | White | Black | All races | White | Black | |
| Pacific | | | | | | | |
| Alaska (NPCR) | No. of patients | 100 | 62 | - | 238 | 141 | 16 |
| | Localized (%) | 28.0 | 22.6 | 50.0 | 43.7 | 41.8 | 56.3 |
| | Regional (%) | 22.0 | 21.0 | 25.0 | 23.9 | 23.4 | 18.8 |
| | Distant (%) | 18.0 | 16.1 | 0.0 | 16.4 | 14.9 | 6.3 |
| | Unknown (%) | 32.0 | 40.3 | 25.0 | 16.0 | 19.9 | 18.8 |
| California (NPCR/SEER) | No. of patients | 6,206 | 4,044 | 456 | 16,772 | 11,251 | 1,285 |
| | Localized (%) | 38.2 | 38.0 | 32.9 | 43.1 | 42.7 | 38.7 |
| | Regional (%) | 27.4 | 26.1 | 32.2 | 28.0 | 27.4 | 31.1 |
| | Distant (%) | 18.1 | 17.8 | 21.3 | 17.5 | 17.7 | 21.0 |
| | Unknown (%) | 16.3 | 18.1 | 13.6 | 11.5 | 12.2 | 9.2 |
| Hawaii (SEER) | No. of patients | 364 | 49 | - | 818 | 185 | 11 |
| | Localized (%) | 40.7 | 38.8 | 100.0 | 41.7 | 36.2 | 18.2 |
| | Regional (%) | 34.3 | 36.7 | 0.0 | 27.9 | 28.1 | 27.3 |
| | Distant (%) | 19.8 | 16.3 | 0.0 | 18.2 | 20.0 | 45.5 |
| | Unknown (%) | 5.2 | 8.2 | 0.0 | 12.2 | 15.7 | 9.1 |
| Oregon (NPCR) | No. of patients | 430 | 362 | - | 1,440 | 1,219 | 39 |
| | Localized (%) | 24.9 | 24.9 | 33.3 | 36.6 | 36.3 | 35.9 |
| | Regional (%) | 26.0 | 24.3 | 33.3 | 29.7 | 28.9 | 25.6 |
| | Distant (%) | 18.6 | 19.1 | 11.1 | 18.4 | 18.5 | 15.4 |
| | Unknown (%) | 30.5 | 31.8 | 22.2 | 15.3 | 16.3 | 23.1 |
| Washington (NPCR/SEER) | No. of patients | 896 | 701 | 34 | 2,169 | 1,613 | 119 |
| | Localized (%) | 37.9 | 37.1 | 41.2 | 38.7 | 36.9 | 48.7 |
| | Regional (%) | 33.4 | 31.7 | 44.1 | 31.0 | 31.1 | 31.9 |
| | Distant (%) | 14.4 | 14.8 | 11.8 | 18.9 | 19.4 | 16.8 |
| | Unknown (%) | 14.3 | 16.4 | 2.9 | 11.3 | 12.6 | 2.5 |

| Years | NS | 2001-2003 | | | | | | 2004-2009 | | | | | |
|---------------------------|----|-----------|-------------|--------|-------------|--------|-------------|-----------|-------------|--------|-------------|--------|-------------|
| | | All races | | White | | Black | | All races | | White | | Black | |
| | | 95% CI | 95% CI | 95% CI | 95% CI | 95% CI | 95% CI | 95% CI | 95% CI | 95% CI | 95% CI | 95% CI | |
| Oklahoma (NPCR) | 1 | 26.3 | 22.1 - 30.6 | 27.4 | 22.4 - 32.3 | 27.7 | 13.5 - 42.0 | 31.5 | 28.7 - 34.3 | 32.6 | 29.3 - 35.8 | 36.1 | 24.7 - 47.6 |
| | 3 | 11.9 | 8.7 - 15.1 | 11.3 | 7.6 - 15.0 | 18.2 | 5.8 - 30.5 | 16.2 | 13.6 - 18.9 | 15.7 | 12.7 - 18.6 | 23.3 | 12.9 - 33.7 |
| | 5 | 8.1 | 5.4 - 10.8 | 6.9 | 4.0 - 9.8 | 13.2 | 1.8 - 24.5 | 10.9 | 8.0 - 13.9 | 11.1 | 8.1 - 14.2 | 23.7 | 12.6 - 34.8 |
| Texas (NPCR) | 1 | 33.2 | 31.6 - 34.8 | 33.8 | 32.0 - 35.6 | 28.8 | 23.3 - 34.4 | 37.0 | 35.9 - 38.0 | 37.3 | 36.1 - 38.5 | 29.5 | 26.4 - 32.7 |
| | 3 | 16.4 | 15.0 - 17.7 | 16.3 | 14.9 - 17.7 | 12.7 | 8.7 - 16.7 | 19.7 | 18.7 - 20.8 | 19.8 | 18.7 - 21.0 | 13.1 | 10.2 - 16.0 |
| | 5 | 12.0 | 10.9 - 13.2 | 11.9 | 10.6 - 13.2 | 10.0 | 6.0 - 14.1 | 14.1 | 12.9 - 15.3 | 14.3 | 12.9 - 15.6 | 8.0 | 5.8 - 10.3 |
| MIDWEST | | | | | | | | | | | | | |
| East North Central | | | | | | | | | | | | | |
| Michigan (NPCR) | 1 | 28.2 | 25.7 - 30.6 | 29.5 | 26.7 - 32.3 | 24.5 | 18.4 - 30.6 | 34.3 | 32.6 - 36.1 | 35.6 | 33.6 - 37.7 | 27.6 | 23.5 - 31.6 |
| | 3 | 15.6 | 13.6 - 17.6 | 15.9 | 13.6 - 18.2 | 14.3 | 9.3 - 19.4 | 19.2 | 17.5 - 20.9 | 19.8 | 17.8 - 21.8 | 16.7 | 12.8 - 20.6 |
| | 5 | 11.0 | 9.2 - 12.8 | 11.6 | 9.5 - 13.7 | 7.9 | 4.3 - 11.5 | 15.2 | 13.3 - 17.1 | 16.4 | 14.2 - 18.6 | 6.1 | 4.1 - 8.0 |
| Ohio (NPCR) | 1 | 27.0 | 24.5 - 29.5 | 28.4 | 25.5 - 31.2 | 24.4 | 18.4 - 30.5 | 33.1 | 31.3 - 34.8 | 33.5 | 31.6 - 35.5 | 29.9 | 25.4 - 34.4 |
| | 3 | 12.7 | 10.8 - 14.7 | 14.1 | 11.8 - 16.4 | 7.8 | 4.3 - 11.2 | 17.2 | 15.6 - 18.9 | 17.1 | 15.3 - 19.0 | 15.8 | 11.9 - 19.6 |
| | 5 | 9.1 | 7.4 - 10.8 | 10.3 | 8.2 - 12.3 | 4.7 | 2.1 - 7.3 | 12.7 | 10.8 - 14.5 | 12.2 | 10.2 - 14.3 | 13.9 | 10.0 - 17.7 |
| Wisconsin (NPCR) | 1 | 34.4 | 30.8 - 38.1 | 34.9 | 31.1 - 38.8 | 38.2 | 24.1 - 52.4 | 40.5 | 37.9 - 43.1 | 41.2 | 38.4 - 44.1 | 30.7 | 21.7 - 39.7 |
| | 3 | 16.8 | 13.8 - 19.9 | 16.8 | 13.5 - 20.0 | 22.8 | 10.6 - 35.0 | 20.4 | 17.8 - 22.9 | 20.9 | 18.1 - 23.6 | 13.4 | 7.1 - 19.7 |
| | 5 | 13.9 | 10.9 - 16.9 | 14.0 | 10.8 - 17.2 | 13.9 | 4.0 - 23.9 | 11.5 | 9.0 - 14.1 | 12.0 | 9.2 - 14.7 | 10.1 | 1.6 - 18.6 |
| West North Central | | | | | | | | | | | | | |
| Iowa (SEER) | 1 | 27.1 | 22.0 - 32.2 | 27.5 | 22.5 - 32.4 | - | - | 38.7 | 35.2 - 42.2 | 39.7 | 36.0 - 43.3 | 43.5 | 25.5 - 61.6 |
| | 3 | 14.6 | 10.6 - 18.7 | 15.5 | 11.5 - 19.5 | - | - | 19.4 | 16.0 - 22.9 | 20.7 | 17.1 - 24.4 | 19.8 | 2.2 - 37.3 |
| | 5 | 12.0 | 8.3 - 15.7 | 12.6 | 8.9 - 16.3 | - | - | 16.5 | 12.9 - 20.1 | 17.7 | 13.9 - 21.5 | 19.9 | 2.2 - 37.5 |
| Nebraska (NPCR) | 1 | 32.9 | 27.0 - 38.8 | 34.3 | 28.0 - 40.6 | 37.0 | 10.9 - 63.1 | 40.3 | 36.2 - 44.3 | 41.4 | 37.1 - 45.8 | 38.8 | 24.0 - 53.5 |
| | 3 | 17.3 | 12.6 - 22.0 | 17.5 | 12.5 - 22.4 | 28.5 | 4.2 - 52.9 | 19.9 | 16.0 - 23.8 | 20.6 | 16.5 - 24.7 | 18.5 | 5.3 - 31.7 |
| | 5 | 12.7 | 8.5 - 16.9 | 12.6 | 8.1 - 17.0 | 23.7 | 0.0 - 48.2 | 14.9 | 11.3 - 18.5 | 15.3 | 11.5 - 19.1 | 19.0 | 5.5 - 32.5 |
| WEST | | | | | | | | | | | | | |
| Mountain | | | | | | | | | | | | | |
| Colorado (NPCR) | 1 | 29.8 | 25.7 - 33.8 | 28.7 | 24.3 - 33.1 | 41.2 | 24.5 - 57.9 | 37.5 | 34.7 - 40.4 | 36.7 | 33.7 - 39.7 | 27.8 | 16.8 - 38.7 |
| | 3 | 13.9 | 10.9 - 17.0 | 13.8 | 10.5 - 17.1 | 9.8 | 0.1 - 19.5 | 20.1 | 17.5 - 22.8 | 19.6 | 16.8 - 22.4 | 10.9 | 1.5 - 20.3 |
| | 5 | 11.5 | 8.7 - 14.3 | 11.3 | 8.3 - 14.4 | 6.9 | 0.0 - 15.0 | 16.0 | 13.2 - 18.9 | 15.6 | 12.6 - 18.6 | 11.0 | 1.5 - 20.5 |
| Idaho (NPCR) | 1 | 31.5 | 22.5 - 40.5 | 32.1 | 22.8 - 41.4 | - | - | 36.8 | 31.5 - 42.2 | 37.6 | 32.0 - 43.1 | - | - |
| | 3 | 18.4 | 11.2 - 25.6 | 18.4 | 10.9 - 25.9 | - | - | 19.4 | 14.2 - 24.6 | 20.0 | 14.6 - 25.4 | - | - |
| | 5 | 15.4 | 8.1 - 22.6 | 15.2 | 7.7 - 22.7 | - | - | 11.5 | 6.5 - 16.4 | 11.8 | 6.6 - 17.1 | - | - |
| Montana (NPCR) | 1 | 29.1 | 19.1 - 39.1 | 28.6 | 18.1 - 39.1 | - | - | 35.9 | 29.6 - 42.2 | 38.2 | 31.3 - 45.1 | - | - |
| | 3 | 14.7 | 7.3 - 22.1 | 15.2 | 7.5 - 22.8 | - | - | 15.4 | 9.7 - 21.0 | 16.8 | 10.6 - 23.0 | - | - |
| | 5 | 13.9 | 5.7 - 22.1 | 13.9 | 5.2 - 22.7 | - | - | 11.1 | 5.5 - 16.6 | 11.8 | 5.9 - 17.8 | - | - |
| New Mexico (SEER) | 1 | 27.2 | 22.4 - 32.0 | 25.9 | 20.9 - 31.0 | - | - | 32.0 | 28.6 - 35.3 | 31.5 | 27.9 - 35.1 | 37.2 | 13.1 - 61.4 |
| | 3 | 11.2 | 7.7 - 14.7 | 11.0 | 7.3 - 14.6 | - | - | 13.9 | 11.1 - 16.8 | 13.4 | 10.3 - 16.4 | 18.9 | 0.0 - 41.2 |
| | 5 | 7.0 | 4.3 - 9.7 | 6.9 | 4.0 - 9.7 | - | - | 9.7 | 7.1 - 12.4 | 9.9 | 7.0 - 12.9 | - | - |
| Utah (SEER) | 1 | 28.8 | 21.6 - 36.0 | 29.4 | 22.0 - 36.9 | - | - | 38.7 | 33.7 - 43.7 | 40.4 | 35.0 - 45.7 | 27.4 | 3.6 - 51.2 |
| | 3 | 13.7 | 8.3 - 19.1 | 13.2 | 7.7 - 18.6 | - | - | 18.9 | 14.3 - 23.6 | 20.7 | 15.6 - 25.7 | 0.2 | 0.0 - 0.5 |
| | 5 | 11.4 | 6.5 - 16.3 | 11.7 | 6.5 - 17.0 | - | - | 9.8 | 5.9 - 13.7 | 10.7 | 6.4 - 15.0 | - | - |
| Wyoming (NPCR) | 1 | 30.4 | 16.3 - 44.4 | 32.8 | 17.8 - 47.7 | - | - | 31.8 | 24.2 - 39.5 | 32.3 | 24.6 - 40.0 | - | - |
| | 3 | 5.4 | 0.0 - 12.0 | 5.9 | 0.0 - 12.9 | - | - | 16.0 | 9.9 - 22.1 | 16.3 | 10.1 - 22.5 | - | - |
| | 5 | 2.7 | 0.0 - 7.0 | 3.0 | 0.0 - 7.6 | - | - | 8.1 | 2.2 - 13.9 | 8.1 | 2.3 - 14.0 | - | - |
| Pacific | | | | | | | | | | | | | |
| Alaska (NPCR) | 1 | 33.3 | 23.4 - 43.2 | 34.3 | 22.6 - 46.1 | - | - | 38.5 | 31.6 - 45.4 | 37.1 | 28.2 - 46.0 | 31.5 | 10.0 - 52.9 |
| | 3 | 11.7 | 6.2 - 17.2 | 14.7 | 6.0 - 23.4 | - | - | 25.9 | 18.9 - 32.8 | 21.4 | 14.3 - 28.5 | 8.1 | 0.0 - 20.0 |
| | 5 | 9.0 | 3.9 - 14.0 | 9.8 | 2.6 - 17.0 | - | - | 16.6 | 9.4 - 23.7 | 13.1 | 6.9 - 19.4 | - | - |
| California (NPCR/SEER) | 1 | 32.9 | 31.7 - 34.1 | 31.2 | 29.8 - 32.7 | 25.6 | 21.4 - 29.8 | 39.5 | 38.7 - 40.3 | 37.2 | 36.2 - 38.2 | 31.5 | 28.4 - 34.5 |
| | 3 | 16.3 | 15.3 - 17.3 | 14.4 | 13.3 - 15.6 | 10.0 | 7.4 - 12.6 | 21.1 | 20.3 - 21.9 | 18.7 | 17.7 - 19.6 | 16.1 | 13.2 - 18.9 |
| | 5 | 11.4 | 10.6 - 12.3 | 10.1 | 9.1 - 11.1 | 7.2 | 5.1 - 9.3 | 14.8 | 13.8 - 15.8 | 12.8 | 11.7 - 13.9 | 11.7 | 8.5 - 14.9 |
| Hawaii (SEER) | 1 | 34.8 | 29.8 - 39.8 | 37.3 | 23.9 - 50.7 | - | - | 40.5 | 36.9 - 44.1 | 34.3 | 26.9 - 41.7 | 53.6 | 25.1 - 82.2 |
| | 3 | 18.2 | 14.2 - 22.3 | 21.2 | 9.7 - 32.7 | - | - | 23.1 | 19.4 - 26.8 | 23.0 | 15.9 - 30.1 | 21.4 | 0.0 - 44.1 |
| | 5 | 15.2 | 11.3 - 19.1 | 19.8 | 8.4 - 31.1 | - | - | 13.2 | 8.8 - 17.6 | 16.8 | 9.0 - 24.7 | 21.8 | 0.0 - 44.9 |
| Oregon (NPCR) | 1 | 26.8 | 22.6 - 31.1 | 25.5 | 20.9 - 30.1 | - | - | 34.7 | 31.9 - 37.5 | 33.2 | 30.2 - 36.2 | 42.1 | 26.2 - 57.9 |
| | 3 | 10.2 | 7.2 - 13.2 | 8.6 | 5.7 - 11.6 | - | - | 15.7 | 13.1 - 18.2 | 14.1 | 11.3 - 16.8 | 24.3 | 8.8 - 39.8 |
| | 5 | 6.9 | 4.3 - 9.5 | 5.9 | 3.3 - 8.5 | - | - | 11.2 | 8.7 - 13.8 | 10.1 | 7.4 - 12.8 | 6.3 | 0.0 - 15.3 |
| Washington (NPCR) | 1 | 32.2 | 29.0 - 35.4 | 31.2 | 27.6 - 34.9 | 35.8 | 19.9 - 51.7 | 40.3 | 38.1 - 42.5 | 38.4 | 35.9 - 40.9 | 49.0 | 39.4 - 58.7 |
| | 3 | 15.3 | 12.8 - 17.8 | 13.9 | 11.2 - 16.7 | 21.1 | 7.4 - 34.8 | 22.1 | 20.0 - 24.2 | 20.4 | 18.0 - 22.7 | 21.6 | 12.5 - 30.8 |
| | 5 | 11.8 | 9.5 - 14.1 | 10.7 | 8.1 - 13.2 | 12.3 | 1.6 - 23.1 | 14.7 | 12.4 - 17.0 | 13.9 | 11.3 - 16.4 | 8.1 | 4.6 - 11.7 |

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

| SEER Summary Stage | | 2001-2003 | | | | | | 2004-2009 | | | | | |
|---------------------------|------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|
| | | All races | | White | | Black | | All races | | White | | Black | |
| | | NS (%) | 95% CI | NS (%) | 95% CI | NS (%) | 95% CI | NS (%) | 95% CI | NS (%) | 95% CI | NS (%) | 95% CI |
| UNITED STATES | | | | | | | | | | | | | |
| All stages | 12.2 | 11.8 - 12.5 | 11.7 | 11.3 - 12.1 | 9.1 | 8.0 - 10.2 | 14.8 | 14.4 - 15.2 | 14.3 | 13.8 - 14.8 | 11.4 | 10.3 - 12.5 | |
| Localized | 22.9 | 22.1 - 23.8 | 22.4 | 21.4 - 23.4 | 15.8 | 13.3 - 18.2 | 25.7 | 24.9 - 26.5 | 24.8 | 23.9 - 25.7 | 20.8 | 18.4 - 23.3 | |
| Regional | 8.3 | 7.6 - 9.0 | 7.6 | 6.8 - 8.4 | 8.3 | 6.3 - 10.4 | 9.5 | 8.8 - 10.2 | 9.2 | 8.4 - 9.9 | 7.1 | 5.4 - 8.9 | |
| Distant | 2.8 | 2.4 - 3.3 | 2.4 | 2.0 - 2.9 | 2.5 | 1.2 - 3.8 | 3.5 | 3.0 - 4.0 | 2.9 | 2.3 - 3.4 | 3.8 | 2.6 - 5.1 | |
| Unknown | 8.2 | 7.6 - 8.9 | 7.9 | 7.2 - 8.7 | 7.0 | 5.3 - 8.8 | 8.9 | 8.2 - 9.6 | 9.0 | 8.1 - 9.8 | 6.2 | 4.6 - 7.8 | |
| NORTHEAST | | | | | | | | | | | | | |
| New England | | | | | | | | | | | | | |
| Connecticut (SEER) | All stages | 12.4 | 9.2 - 15.5 | 12.8 | 9.4 - 16.2 | 13.5 | 3.4 - 23.5 | 14.5 | 11.4 - 17.7 | 14.9 | 11.4 - 18.5 | 16.1 | 7.7 - 24.4 |
| | Localized | 23.6 | 17.0 - 30.2 | 25.3 | 18.2 - 32.4 | 8.9 | 0.0 - 22.0 | 23.7 | 17.2 - 30.3 | 23.6 | 16.6 - 30.6 | 22.4 | 6.2 - 38.6 |
| | Regional | 7.7 | 3.4 - 11.9 | 4.3 | 1.3 - 7.2 | 34.3 | 8.8 - 59.8 | 8.1 | 4.7 - 11.5 | 8.8 | 4.8 - 12.8 | - | - |
| | Distant | 1.6 | 0.0 - 3.8 | 0.0 | 0.0 - 0.0 | - | - | 5.8 | 2.6 - 9.0 | 4.1 | 0.6 - 7.6 | 15.1 | 0.5 - 29.7 |
| | Unknown | 8.6 | 3.9 - 13.2 | 9.6 | 4.5 - 14.8 | 0.0 | - | 9.5 | 6.0 - 13.1 | 9.3 | 5.7 - 13.0 | - | - |
| Massachusetts (NPCR) | All stages | 14.0 | 11.7 - 16.4 | 13.1 | 10.6 - 15.5 | 10.3 | 3.4 - 17.2 | 15.6 | 13.0 - 18.2 | 13.6 | 10.9 - 16.4 | 20.3 | 13.0 - 27.6 |
| | Localized | 31.0 | 25.4 - 36.6 | 28.5 | 22.9 - 34.0 | 22.2 | 3.7 - 40.7 | 28.1 | 23.0 - 33.2 | 26.5 | 21.1 - 31.9 | 14.6 | 0.0 - 32.5 |
| | Regional | 8.0 | 4.6 - 11.4 | 7.9 | 4.6 - 11.3 | 9.9 | 0.0 - 21.0 | 10.5 | 6.7 - 14.4 | 9.5 | 5.6 - 13.4 | 9.3 | 0.0 - 20.2 |
| | Distant | 2.6 | 0.5 - 4.6 | 2.2 | 0.4 - 4.0 | 0.0 | - | 4.7 | 2.4 - 7.0 | 2.2 | 0.0 - 4.5 | - | - |
| | Unknown | 3.8 | 1.4 - 6.1 | 2.8 | 1.1 - 4.6 | 0.0 | - | 3.9 | 1.8 - 6.0 | 1.6 | 0.5 - 2.8 | 10.0 | 0.0 - 20.9 |
| New Hampshire (NPCR) | All stages | 12.2 | 6.9 - 17.5 | 10.9 | 5.7 - 16.1 | - | - | 12.5 | 8.6 - 16.4 | 12.4 | 8.3 - 16.4 | - | - |
| | Localized | 32.9 | 16.2 - 49.5 | 33.7 | 15.8 - 51.6 | - | - | 24.2 | 15.9 - 32.4 | 25.6 | 17.2 - 34.1 | - | - |
| | Regional | 10.1 | 0.2 - 20.0 | 4.3 | 0.0 - 10.8 | - | - | 10.0 | 2.6 - 17.3 | 8.7 | 1.6 - 15.9 | - | - |
| | Distant | 0.0 | - | 0.0 | - | - | - | - | - | - | - | - | - |
| | Unknown | 2.3 | 0.0 - 6.1 | 2.5 | 0.0 - 6.5 | - | - | 3.5 | 0.0 - 8.5 | 4.0 | 0.0 - 9.6 | - | - |
| Rhode Island (NPCR) | All stages | 12.8 | 7.7 - 17.8 | 11.7 | 6.8 - 16.6 | 20.6 | 0.0 - 42.9 | 10.7 | 6.8 - 14.7 | 9.9 | 6.1 - 13.6 | 14.3 | 0.0 - 31.3 |
| | Localized | 22.2 | 10.0 - 34.5 | 19.8 | 7.5 - 32.1 | - | - | - | - | - | - | - | - |
| | Regional | 11.3 | 2.4 - 20.3 | 12.5 | 2.7 - 22.4 | - | - | - | - | - | - | - | - |
| | Distant | 8.5 | 0.0 - 18.2 | 5.7 | 0.0 - 14.2 | - | - | - | - | - | - | - | - |
| | Unknown | 4.5 | 0.0 - 10.2 | 4.6 | 0.0 - 10.4 | - | - | - | - | - | - | - | - |
| Mid Atlantic | | | | | | | | | | | | | |
| New Jersey (NPCR/SEER) | All stages | 12.6 | 10.7 - 14.4 | 12.3 | 10.2 - 14.4 | 6.9 | 3.8 - 10.0 | 14.8 | 12.8 - 16.8 | 15.4 | 13.1 - 17.6 | 8.8 | 4.2 - 13.4 |
| | Localized | 23.4 | 19.3 - 27.4 | 23.0 | 18.3 - 27.7 | 21.7 | 11.2 - 32.2 | 23.9 | 20.1 - 27.6 | 25.0 | 20.8 - 29.2 | 16.5 | 7.1 - 25.9 |
| | Regional | 7.9 | 4.7 - 11.1 | 9.0 | 5.2 - 12.8 | 2.5 | 0.0 - 6.5 | 10.0 | 6.5 - 13.5 | 9.3 | 5.6 - 12.9 | 11.2 | 3.3 - 19.0 |
| | Distant | 0.9 | 0.0 - 1.8 | 1.2 | 0.0 - 2.5 | 0.0 | - | 3.4 | 1.6 - 5.2 | 4.1 | 2.0 - 6.2 | 2.2 | 0.0 - 5.0 |
| | Unknown | 12.0 | 8.6 - 15.3 | 10.2 | 7.0 - 13.5 | 13.3 | 3.5 - 23.0 | 11.1 | 7.7 - 14.5 | 12.0 | 7.9 - 16.0 | - | - |
| New York (NPCR) | All stages | 16.8 | 15.5 - 18.2 | 14.6 | 13.1 - 16.2 | 13.1 | 9.9 - 16.4 | 20.4 | 19.1 - 21.7 | 18.2 | 16.6 - 19.8 | 16.5 | 13.5 - 19.5 |
| | Localized | 32.0 | 28.8 - 35.2 | 30.3 | 26.5 - 34.1 | 18.2 | 11.3 - 25.2 | 34.0 | 31.4 - 36.7 | 30.2 | 27.0 - 33.4 | 30.2 | 23.9 - 36.4 |
| | Regional | 14.9 | 12.2 - 17.6 | 11.0 | 8.1 - 13.8 | 18.5 | 11.7 - 25.3 | 13.9 | 11.6 - 16.2 | 13.1 | 10.3 - 15.9 | 12.2 | 8.0 - 16.5 |
| | Distant | 5.9 | 4.1 - 7.8 | 4.0 | 2.2 - 5.8 | 3.3 | 1.3 - 5.3 | 5.3 | 3.7 - 6.8 | 4.1 | 2.6 - 5.6 | 9.1 | 5.3 - 12.9 |
| | Unknown | 10.5 | 8.6 - 12.4 | 8.7 | 6.5 - 10.9 | 9.0 | 4.3 - 13.7 | 13.5 | 11.1 - 16.0 | 13.6 | 10.8 - 16.5 | 4.1 | 1.7 - 6.5 |
| Pennsylvania (NPCR) | All stages | 12.3 | 10.7 - 13.9 | 12.2 | 10.4 - 14.0 | 7.9 | 4.8 - 11.1 | 15.1 | 13.5 - 16.8 | 14.7 | 12.8 - 16.5 | 13.4 | 10.2 - 16.5 |
| | Localized | 23.5 | 19.9 - 27.0 | 23.6 | 19.6 - 27.5 | 9.9 | 5.2 - 14.5 | 25.4 | 22.1 - 28.7 | 25.6 | 21.9 - 29.3 | 23.4 | 16.2 - 30.6 |
| | Regional | 7.8 | 5.3 - 10.3 | 7.2 | 4.5 - 9.8 | 8.1 | 2.2 - 14.1 | 8.7 | 6.4 - 11.1 | 9.4 | 6.6 - 12.2 | 10.6 | 5.4 - 15.7 |
| | Distant | 1.5 | 0.3 - 2.6 | 1.3 | 0.0 - 2.6 | 0.0 | 0.0 - 0.0 | 5.4 | 3.5 - 7.2 | 4.5 | 2.7 - 6.4 | 5.1 | 1.1 - 9.1 |
| | Unknown | 9.2 | 6.2 - 12.3 | 6.7 | 3.8 - 9.6 | 8.7 | 2.9 - 14.5 | 8.0 | 5.2 - 10.9 | 5.9 | 3.2 - 8.6 | 11.5 | 2.8 - 20.2 |
| SOUTH | | | | | | | | | | | | | |
| South Atlantic | | | | | | | | | | | | | |
| Delaware (NPCR) | All stages | 12.1 | 5.8 - 18.3 | 13.3 | 6.3 - 20.3 | 7.6 | 0.0 - 18.9 | 14.5 | 8.0 - 21.1 | 13.5 | 7.1 - 19.9 | 16.8 | 3.0 - 30.5 |
| | Localized | 25.5 | 11.1 - 39.8 | 27.8 | 11.4 - 44.2 | - | - | 24.7 | 13.0 - 36.4 | 17.5 | 9.6 - 25.3 | 40.5 | 13.6 - 67.5 |
| | Regional | 10.2 | 0.0 - 22.2 | 15.6 | 0.0 - 33.5 | - | - | 0.0 | 0.0 - 0.1 | 9.1 | 0.0 - 19.0 | 0.7 | 0.0 - 2.3 |
| | Distant | 0.0 | - | 0.0 | - | - | - | - | - | - | - | - | - |
| | Unknown | 0.0 | - | 0.0 | - | - | - | 5.9 | 0.0 - 14.5 | 8.4 | 0.0 - 20.5 | - | - |
| Florida (NPCR) | All stages | 14.8 | 13.3 - 16.2 | 14.5 | 12.9 - 16.1 | 14.3 | 9.0 - 19.6 | 20.9 | 19.3 - 22.4 | 20.8 | 19.1 - 22.6 | 17.4 | 13.7 - 21.1 |
| | Localized | 26.4 | 23.0 - 29.7 | 26.8 | 23.2 - 30.4 | 14.8 | 6.6 - 22.9 | 32.8 | 29.9 - 35.6 | 32.7 | 29.7 - 35.7 | 30.3 | 22.3 - 38.3 |
| | Regional | 10.7 | 7.9 - 13.5 | 9.4 | 6.6 - 12.2 | 15.8 | 6.7 - 24.8 | 14.8 | 11.8 - 17.7 | 14.5 | 11.3 - 17.8 | 9.5 | 4.9 - 14.1 |
| | Distant | 5.5 | 3.4 - 7.5 | 4.7 | 2.7 - 6.7 | 6.9 | 0.7 - 13.1 | 8.1 | 5.8 - 10.4 | 7.0 | 4.6 - 9.3 | 9.7 | 3.3 - 16.1 |
| | Unknown | 12.5 | 10.1 - 15.0 | 12.4 | 9.7 - 15.0 | 14.4 | 6.5 - 22.3 | 16.3 | 13.3 - 19.2 | 16.4 | 13.0 - 19.7 | 11.2 | 6.0 - 16.5 |
| Georgia (NPCR/SEER) | All stages | 7.6 | 5.6 - 9.6 | 8.2 | 5.7 - 10.6 | 4.5 | 1.7 - 7.2 | 12.5 | 10.4 - 14.6 | 13.3 | 10.8 - 15.7 | 10.9 | 6.3 - 15.4 |
| | Localized | 16.5 | 11.9 - 21.2 | 19.4 | 13.7 - 25.1 | 6.9 | 1.5 - 12.2 | 22.7 | 18.6 - 26.9 | 22.7 | 18.0 - 27.3 | 24.4 | 15.3 - 33.6 |
| | Regional | 2.4 | 0.0 - 4.9 | 2.6 | 0.0 - 5.9 | 2.0 | 0.0 - 5.2 | 6.4 | 3.7 - 9.2 | 8.3 | 4.8 - 11.8 | 4.4 | 1.7 - 7.0 |
| | Distant | 0.0 | 0.0 - 0.0 | 0.0 | 0.0 - 0.0 | 0.1 | 0.0 - 0.3 | 4.1 | 1.8 - 6.4 | 5.0 | 2.1 - 7.8 | 3.3 | 0.0 - 6.8 |
| | Unknown | 5.5 | 2.5 - 8.5 | 3.2 | 1.0 - 5.3 | 9.2 | 0.5 - 17.8 | 8.4 | 4.6 - 12.2 | 8.0 | 4.1 - 11.9 | 8.7 | 0.0 - 18.1 |
| Maryland (NPCR) | All stages | 10.7 | 8.1 - 13.3 | 9.7 | 6.7 - 12.7 | 10.8 | 6.1 - 15.5 | 13.4 | 10.8 - 16.0 | 13.5 | 10.6 - 16.5 | 8.9 | 5.0 - 12.7 |
| | Localized | - | - | - | - | - | - | - | - | - | - | - | - |
| | Regional | - | - | - | - | - | - | - | - | - | - | - | - |
| | Distant | - | - | - | - | - | - | - | - | - | - | - | - |
| | Unknown | - | - | - | - | - | - | - | - | - | - | - | - |

| | | 2001-2003 | | | | | | 2004-2009 | | | | | |
|---------------------------|---------------|-----------|-------------|--------|-------------|--------|------------|-----------|-------------|--------|-------------|--------|-------------|
| | | All races | | White | | Black | | All races | | White | | Black | |
| SEER | Summary Stage | NS (%) | 95% CI | NS (%) | 95% CI | NS (%) | 95% CI | NS (%) | 95% CI | NS (%) | 95% CI | NS (%) | 95% CI |
| North Carolina (NPCR) | All stages | 10.2 | 8.1 - 12.4 | 10.7 | 8.2 - 13.2 | 5.7 | 2.8 - 8.6 | 12.0 | 9.9 - 14.1 | 13.3 | 10.8 - 15.9 | 5.9 | 2.5 - 9.3 |
| | Localized | 17.5 | 13.1 - 21.8 | 17.6 | 12.7 - 22.5 | 9.7 | 3.3 - 16.2 | 21.7 | 17.2 - 26.2 | 25.3 | 19.9 - 30.6 | 6.4 | 3.0 - 9.9 |
| | Regional | 6.7 | 3.2 - 10.1 | 5.1 | 1.8 - 8.4 | 11.9 | 2.6 - 21.1 | 6.2 | 3.5 - 8.9 | 6.0 | 3.0 - 9.0 | 3.2 | 0.0 - 7.3 |
| | Distant | 2.7 | 0.8 - 4.6 | 3.3 | 1.1 - 5.4 | 0.0 | - | 3.4 | 1.2 - 5.6 | 3.1 | 0.9 - 5.2 | - | - |
| | Unknown | 7.4 | 3.9 - 10.8 | 8.0 | 4.1 - 12.0 | 1.9 | 0.3 - 3.6 | 6.0 | 2.9 - 9.0 | 4.6 | 2.1 - 7.2 | 10.3 | 2.2 - 18.5 |
| South Carolina (NPCR) | All stages | 10.0 | 7.2 - 12.7 | 11.6 | 8.2 - 15.1 | 6.7 | 2.2 - 11.1 | 10.4 | 7.7 - 13.1 | 11.9 | 8.5 - 15.2 | 6.5 | 2.5 - 10.4 |
| | Localized | 18.2 | 12.7 - 23.7 | 20.0 | 13.4 - 26.5 | 12.7 | 1.3 - 24.2 | 20.8 | 15.4 - 26.2 | 24.5 | 18.2 - 30.9 | 13.5 | 5.1 - 21.9 |
| | Regional | 7.9 | 3.1 - 12.8 | 10.6 | 4.5 - 16.7 | 5.4 | 0.0 - 13.8 | 4.3 | 1.4 - 7.1 | 3.8 | 0.0 - 7.8 | 0.1 | 0.0 - 0.2 |
| | Distant | 0.0 | - | 0.0 | - | 0.0 | - | 3.5 | 0.1 - 6.8 | 5.2 | 0.3 - 10.1 | - | - |
| | Unknown | 4.8 | 1.9 - 7.8 | 4.2 | 1.0 - 7.4 | 7.6 | 0.0 - 15.5 | 6.0 | 2.8 - 9.2 | 5.3 | 0.4 - 10.2 | 6.0 | 0.0 - 13.4 |
| West Virginia (NPCR) | All stages | 6.3 | 3.1 - 9.5 | 6.6 | 3.3 - 10.0 | - | - | 9.2 | 5.4 - 13.1 | 7.9 | 4.5 - 11.4 | 9.0 | 0.0 - 21.3 |
| | Localized | 11.5 | 2.9 - 20.1 | 11.9 | 3.0 - 20.8 | - | - | 16.2 | 8.7 - 23.7 | 16.9 | 9.1 - 24.7 | - | - |
| | Regional | 15.6 | 3.6 - 27.6 | 16.1 | 3.8 - 28.3 | - | - | 15.2 | 6.0 - 24.5 | 15.2 | 5.9 - 24.5 | - | - |
| | Distant | 3.0 | 0.0 - 7.4 | 3.1 | 0.0 - 7.7 | - | - | 8.3 | 1.5 - 15.1 | 9.0 | 1.7 - 16.3 | - | - |
| | Unknown | 0.0 | - | 0.0 | - | - | - | 2.2 | 0.0 - 5.5 | 2.0 | 0.0 - 5.0 | - | - |
| East South Central | | | | | | | | | | | | | |
| Alabama (NPCR) | All stages | 8.3 | 5.6 - 10.9 | 7.3 | 4.5 - 10.0 | 7.8 | 3.3 - 12.3 | 9.8 | 7.3 - 12.3 | 11.4 | 8.2 - 14.6 | 4.5 | 1.4 - 7.7 |
| | Localized | 15.1 | 9.7 - 20.5 | 13.2 | 7.5 - 18.9 | 24.2 | 9.9 - 38.6 | 19.7 | 15.4 - 24.0 | 20.3 | 15.9 - 24.6 | 13.9 | 4.1 - 23.8 |
| | Regional | 5.3 | 1.3 - 9.2 | 5.5 | 1.0 - 10.0 | 4.3 | 0.0 - 11.0 | 3.4 | 1.2 - 5.6 | 5.5 | 2.6 - 8.5 | 0.1 | 0.0 - 0.3 |
| | Distant | 3.4 | 0.0 - 7.9 | 1.1 | 0.0 - 2.4 | 0.0 | - | 2.8 | 0.0 - 5.7 | 3.2 | 0.1 - 6.3 | 0.3 | 0.0 - 0.9 |
| | Unknown | 4.7 | 1.5 - 7.9 | 4.0 | 0.8 - 7.1 | 6.0 | 0.0 - 13.0 | 2.8 | 0.5 - 5.1 | 3.8 | 1.0 - 6.5 | 0.1 | 0.0 - 0.3 |
| Kentucky (NPCR/SEER) | All stages | 10.3 | 7.4 - 13.2 | 10.3 | 7.3 - 13.3 | 11.9 | 1.8 - 21.9 | 11.2 | 8.5 - 14.0 | 11.6 | 8.6 - 14.5 | 9.8 | 1.8 - 17.8 |
| | Localized | 21.9 | 15.7 - 28.2 | 21.8 | 15.4 - 28.2 | 24.2 | 2.8 - 45.6 | 18.8 | 13.7 - 24.0 | 20.0 | 15.0 - 25.1 | 16.5 | 1.6 - 31.4 |
| | Regional | 2.2 | 0.0 - 4.5 | 1.4 | 0.0 - 3.6 | 8.3 | 0.0 - 20.9 | 10.6 | 6.5 - 14.6 | 11.6 | 7.3 - 16.0 | - | - |
| | Distant | 0.0 | 0.0 - 0.0 | 0.0 | 0.0 - 0.0 | - | - | 2.1 | 0.3 - 3.9 | 1.8 | 0.0 - 4.3 | 6.4 | 0.0 - 14.1 |
| | Unknown | 6.2 | 3.3 - 9.2 | 7.0 | 3.8 - 10.2 | - | - | 4.4 | 1.5 - 7.3 | 2.9 | 0.5 - 5.4 | - | - |
| Mississippi (NPCR) | All stages | 7.1 | 2.6 - 11.6 | 8.0 | 2.8 - 13.2 | 3.7 | 0.0 - 9.3 | 11.3 | 8.0 - 14.6 | 13.5 | 9.6 - 17.4 | 8.6 | 3.6 - 13.5 |
| | Localized | 12.1 | 2.3 - 21.9 | 13.3 | 1.5 - 25.1 | 10.4 | 0.0 - 25.6 | 23.3 | 16.7 - 29.8 | 24.7 | 17.2 - 32.2 | 19.2 | 5.5 - 32.8 |
| | Regional | 12.2 | 0.2 - 24.2 | 11.8 | 0.0 - 25.5 | - | - | 5.1 | 1.0 - 9.2 | 3.7 | 0.0 - 8.0 | 4.8 | 0.0 - 10.8 |
| | Distant | 0.0 | - | 0.0 | - | - | - | 3.8 | 0.2 - 7.5 | 5.2 | 0.4 - 9.9 | - | - |
| | Unknown | 0.0 | - | 0.0 | - | - | - | 3.7 | 0.0 - 8.5 | 3.2 | 0.0 - 7.8 | 16.0 | 2.0 - 30.0 |
| Tennessee (NPCR) | All stages | 8.2 | 4.6 - 11.7 | 10.0 | 5.9 - 14.1 | 0.0 | - | 11.5 | 9.0 - 13.9 | 10.7 | 8.2 - 13.2 | 12.0 | 5.9 - 18.1 |
| | Localized | 14.6 | 7.8 - 21.3 | 19.0 | 9.0 - 29.0 | - | - | 20.4 | 15.8 - 25.0 | 18.6 | 13.9 - 23.4 | 24.2 | 12.9 - 35.5 |
| | Regional | 5.4 | 0.0 - 11.8 | 6.0 | 0.0 - 13.1 | - | - | 6.6 | 3.7 - 9.6 | 7.5 | 3.9 - 11.1 | 0.2 | 0.0 - 0.7 |
| | Distant | 3.5 | 0.0 - 8.8 | 4.3 | 0.0 - 10.8 | - | - | 0.0 | 0.0 - 0.1 | 0.0 | 0.0 - 0.1 | 5.8 | 0.0 - 12.5 |
| | Unknown | 3.3 | 0.0 - 8.4 | 4.0 | 0.0 - 10.0 | - | - | 6.2 | 2.7 - 9.8 | 3.9 | 0.5 - 7.3 | 0.3 | 0.0 - 1.0 |
| West South Central | | | | | | | | | | | | | |
| Louisiana (NPCR/SEER) | All stages | 9.1 | 6.8 - 11.4 | 11.9 | 8.9 - 15.0 | 5.0 | 2.1 - 7.9 | 9.3 | 7.1 - 11.6 | 11.1 | 8.1 - 14.0 | 6.8 | 3.4 - 10.2 |
| | Localized | 17.9 | 13.2 - 22.7 | 21.8 | 16.0 - 27.6 | 11.4 | 4.2 - 18.7 | 15.1 | 11.2 - 19.0 | 17.8 | 12.8 - 22.8 | 11.2 | 5.4 - 17.0 |
| | Regional | 4.1 | 1.3 - 7.0 | 4.9 | 1.2 - 8.5 | 1.9 | 0.0 - 4.9 | 6.2 | 3.4 - 8.9 | 8.4 | 4.8 - 12.0 | 2.5 | 0.0 - 5.3 |
| | Distant | 0.0 | 0.0 - 0.0 | 0.0 | 0.0 - 0.0 | 0.0 | - | 2.3 | 0.6 - 4.0 | 0.0 | 0.0 - 0.0 | 4.4 | 0.1 - 8.7 |
| | Unknown | 5.0 | 1.2 - 8.8 | 4.2 | 0.0 - 8.5 | 3.3 | 0.0 - 8.5 | 5.3 | 1.0 - 9.7 | 6.0 | 0.4 - 11.7 | 4.2 | 0.0 - 9.3 |
| Oklahoma (NPCR) | All stages | 8.1 | 5.4 - 10.8 | 6.9 | 4.0 - 9.8 | 13.2 | 1.8 - 24.5 | 10.9 | 8.0 - 13.9 | 11.1 | 8.1 - 14.2 | 23.7 | 12.6 - 34.8 |
| | Localized | 15.6 | 10.1 - 21.2 | 12.8 | 7.4 - 18.1 | - | - | 17.3 | 11.7 - 22.8 | 18.6 | 12.9 - 24.3 | 22.8 | 0.0 - 46.4 |
| | Regional | 3.8 | 0.0 - 8.2 | 2.5 | 0.0 - 6.4 | - | - | 3.5 | 0.6 - 6.5 | 5.0 | 1.3 - 8.8 | 8.7 | 0.0 - 21.1 |
| | Distant | 1.2 | 0.0 - 3.0 | 0.0 | 0.0 - 0.0 | - | - | 3.7 | 0.4 - 7.0 | 3.7 | 0.4 - 6.9 | 13.1 | 0.0 - 27.0 |
| | Unknown | 7.2 | 3.5 - 11.0 | 6.3 | 1.3 - 11.3 | 13.8 | 0.0 - 29.5 | 11.0 | 7.3 - 14.6 | 9.9 | 6.2 - 13.7 | 27.3 | 5.8 - 48.7 |
| Texas (NPCR) | All stages | 12.0 | 10.9 - 13.2 | 11.9 | 10.6 - 13.2 | 10.0 | 6.0 - 14.1 | 14.1 | 12.9 - 15.3 | 14.3 | 12.9 - 15.6 | 8.0 | 5.8 - 10.3 |
| | Localized | 19.5 | 17.0 - 22.0 | 19.0 | 16.3 - 21.7 | 16.3 | 9.3 - 23.3 | 22.6 | 20.3 - 24.9 | 22.2 | 19.7 - 24.7 | 15.1 | 10.0 - 20.1 |
| | Regional | 7.5 | 5.3 - 9.8 | 6.6 | 4.3 - 8.9 | 7.9 | 1.3 - 14.5 | 7.9 | 5.8 - 10.0 | 8.4 | 6.1 - 10.7 | 3.7 | 1.1 - 6.3 |
| | Distant | 3.7 | 2.2 - 5.2 | 3.7 | 2.1 - 5.4 | 2.3 | 0.2 - 4.3 | 3.0 | 1.9 - 4.2 | 3.1 | 1.8 - 4.3 | 4.4 | 1.4 - 7.4 |
| | Unknown | 11.4 | 9.4 - 13.4 | 11.0 | 8.9 - 13.1 | 8.0 | 2.0 - 14.0 | 12.2 | 10.0 - 14.4 | 12.6 | 10.2 - 15.0 | 10.2 | 6.4 - 13.9 |
| MIDWEST | | | | | | | | | | | | | |
| East North Central | | | | | | | | | | | | | |
| Michigan (NPCR) | All stages | 11.0 | 9.2 - 12.8 | 11.6 | 9.5 - 13.7 | 7.9 | 4.3 - 11.5 | 15.2 | 13.3 - 17.1 | 16.4 | 14.2 - 18.6 | 6.1 | 4.1 - 8.0 |
| | Localized | 23.9 | 19.3 - 28.4 | 24.5 | 19.4 - 29.5 | 14.2 | 6.2 - 22.1 | 26.7 | 22.2 - 31.2 | 28.3 | 23.4 - 33.2 | 13.5 | 9.3 - 17.8 |
| | Regional | 7.2 | 4.3 - 10.2 | 7.9 | 4.7 - 11.0 | 9.1 | 1.8 - 16.4 | 16.2 | 11.7 - 20.7 | 16.3 | 11.1 - 21.5 | 9.6 | 1.4 - 17.8 |
| | Distant | 1.6 | 0.3 - 2.8 | 1.7 | 0.3 - 3.1 | 3.1 | 0.0 - 6.9 | 5.7 | 3.5 - 7.9 | 5.4 | 3.0 - 7.7 | 2.5 | 0.0 - 5.6 |
| | Unknown | 6.1 | 3.8 - 8.5 | 4.7 | 2.7 - 6.7 | 6.9 | 0.6 - 13.3 | 7.9 | 5.7 - 10.1 | 8.9 | 6.2 - 11.5 | 4.0 | 0.1 - 7.9 |
| Ohio (NPCR) | All stages | 9.1 | 7.4 - 10.8 | 10.3 | 8.2 - 12.3 | 4.7 | 2.1 - 7.3 | 12.7 | 10.8 - 14.5 | 12.2 | 10.2 - 14.3 | 13.9 | 10.0 - 17.7 |
| | Localized | 17.9 | 13.8 - 22.0 | 18.8 | 14.1 - 23.5 | 15.0 | 5.6 - 24.3 | 28.9 | 24.6 - 33.1 | 29.0 | 24.2 - 33.7 | 28.2 | 19.6 - 36.7 |
| | Regional | 5.6 | 3.0 - 8.2 | 6.9 | 3.6 - 10.3 | 5.6 | 0.0 - 12.3 | 8.3 | 5.6 - 11.0 | 8.9 | 5.7 - 12.1 | 12.1 | 5.8 - 18.4 |
| | Distant | 1.7 | 0.4 - 3.1 | 1.9 | 0.3 - 3.4 | 0.0 | - | 3.3 | 1.2 - 5.3 | 2.9 | 1.1 - 4.8 | 5.3 | 0.0 - 10.7 |
| | Unknown | 6.5 | 4.1 - 8.9 | 8.2 | 5.5 - 10.9 | 3.0 | 0.0 - 6.5 | 2.9 | 1.3 - 4.5 | 2.3 | 0.8 - 3.7 | 2.0 | 0.3 - 3.8 |

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

| | | 2001-2003 | | | | | | 2004-2009 | | | | | |
|---------------------------|---------------|-----------|-------------|--------|-------------|--------|------------|-----------|-------------|--------|-------------|--------|-------------|
| | | All races | | White | | Black | | All races | | White | | Black | |
| SEER | Summary Stage | NS (%) | 95% CI | NS (%) | 95% CI | NS (%) | 95% CI | NS (%) | 95% CI | NS (%) | 95% CI | NS (%) | 95% CI |
| Wisconsin (NPCR) | All stages | 13.9 | 10.9 - 16.9 | 14.0 | 10.8 - 17.2 | 13.9 | 4.0 - 23.9 | 11.5 | 9.0 - 14.1 | 12.0 | 9.2 - 14.7 | 10.1 | 1.6 - 18.6 |
| | Localized | - | - | - | - | - | - | - | - | - | - | - | - |
| | Regional | - | - | - | - | - | - | - | - | - | - | - | - |
| | Distant | - | - | - | - | - | - | - | - | - | - | - | - |
| | Unknown | - | - | - | - | - | - | - | - | - | - | - | - |
| West North Central | | | | | | | | | | | | | |
| Iowa (SEER) | All stages | 12.0 | 8.3 - 15.7 | 12.6 | 8.9 - 16.3 | - | - | 16.5 | 12.9 - 20.1 | 17.7 | 13.9 - 21.5 | 19.9 | 2.2 - 37.5 |
| | Localized | 31.9 | 23.8 - 40.0 | 32.8 | 24.3 - 41.3 | - | - | 38.7 | 30.9 - 46.5 | 40.4 | 32.6 - 48.2 | - | - |
| | Regional | 1.2 | 0.0 - 3.0 | 1.2 | 0.0 - 3.0 | - | - | 9.1 | 5.3 - 12.8 | 9.9 | 6.0 - 13.7 | - | - |
| | Distant | 1.8 | 0.0 - 4.9 | 2.0 | 0.0 - 5.3 | - | - | 1.3 | 0.0 - 3.2 | - | - | - | - |
| | Unknown | 1.8 | 0.0 - 4.6 | 1.9 | 0.0 - 5.0 | - | - | 2.7 | 0.0 - 5.9 | 2.7 | 0.0 - 6.0 | - | - |
| Nebraska (NPCR) | All stages | 12.7 | 8.5 - 16.9 | 12.6 | 8.1 - 17.0 | 23.7 | 0.0 - 48.2 | 14.9 | 11.3 - 18.5 | 15.3 | 11.5 - 19.1 | 19.0 | 5.5 - 32.5 |
| | Localized | 23.7 | 15.3 - 32.1 | 23.5 | 14.4 - 32.6 | - | - | 26.5 | 19.5 - 33.5 | 25.7 | 18.6 - 32.8 | 52.8 | 17.3 - 88.3 |
| | Regional | 12.5 | 3.4 - 21.6 | 14.4 | 3.9 - 24.8 | - | - | 12.2 | 7.5 - 16.9 | 14.1 | 7.0 - 21.1 | 15.5 | 0.0 - 32.8 |
| | Distant | 3.6 | 0.0 - 8.8 | 0.0 | - | - | - | - | - | - | - | - | - |
| | Unknown | 4.5 | 0.0 - 9.1 | 4.7 | 0.0 - 9.5 | - | - | 6.9 | 0.7 - 13.0 | 7.5 | 0.8 - 14.2 | - | - |
| WEST Mountain | | | | | | | | | | | | | |
| Colorado (NPCR) | All stages | 11.5 | 8.7 - 14.3 | 11.3 | 8.3 - 14.4 | 6.9 | 0.0 - 15.0 | 16.0 | 13.2 - 18.9 | 15.6 | 12.6 - 18.6 | 11.0 | 1.5 - 20.5 |
| | Localized | 20.5 | 15.1 - 25.9 | 20.4 | 14.7 - 26.2 | - | - | 28.2 | 22.3 - 34.1 | 27.0 | 20.9 - 33.2 | 19.0 | 0.8 - 37.3 |
| | Regional | 7.7 | 3.5 - 12.0 | 7.6 | 3.1 - 12.1 | 0.0 | - | 6.4 | 3.2 - 9.6 | 5.9 | 2.7 - 9.0 | 15.2 | 0.0 - 34.1 |
| | Distant | 3.6 | 0.7 - 6.4 | 0.6 | 0.0 - 1.3 | - | - | 3.0 | 0.2 - 5.9 | 3.2 | 0.2 - 6.1 | - | - |
| | Unknown | 5.3 | 2.4 - 8.2 | 6.4 | 3.0 - 9.8 | - | - | 8.9 | 4.9 - 13.0 | 8.4 | 4.3 - 12.4 | - | - |
| Idaho (NPCR) | All stages | 15.4 | 8.1 - 22.6 | 15.2 | 7.7 - 22.7 | - | - | 11.5 | 6.5 - 16.4 | 11.8 | 6.6 - 17.1 | - | - |
| | Localized | 37.0 | 18.1 - 56.0 | 36.1 | 16.5 - 55.6 | - | - | 22.1 | 12.0 - 32.2 | 23.1 | 12.4 - 33.7 | - | - |
| | Regional | 4.0 | 0.0 - 10.0 | 4.0 | 0.0 - 10.0 | - | - | 6.9 | 0.0 - 15.1 | 6.9 | 0.0 - 15.1 | - | - |
| | Distant | 6.7 | 0.0 - 16.7 | 7.6 | 0.0 - 18.8 | - | - | 1.0 | 0.0 - 3.4 | 1.0 | 0.0 - 3.2 | - | - |
| | Unknown | 6.0 | 0.0 - 15.3 | 6.0 | 0.0 - 15.3 | - | - | 0.7 | 0.0 - 2.3 | 0.9 | 0.0 - 2.7 | - | - |
| Montana (NPCR) | All stages | 13.9 | 5.7 - 22.1 | 13.9 | 5.2 - 22.7 | - | - | 11.1 | 5.5 - 16.6 | 11.8 | 5.9 - 17.8 | - | - |
| | Localized | 27.3 | 7.9 - 46.7 | 32.1 | 10.0 - 54.3 | - | - | 16.4 | 6.1 - 26.8 | 16.4 | 5.8 - 26.9 | - | - |
| | Regional | 6.8 | 0.0 - 16.6 | 7.6 | 0.0 - 18.6 | - | - | 8.1 | 0.0 - 16.2 | 8.8 | 0.0 - 17.9 | - | - |
| | Distant | - | - | - | - | - | - | - | - | - | - | - | - |
| | Unknown | 13.0 | 0.6 - 25.4 | 10.1 | 0.0 - 21.7 | - | - | 21.3 | 2.2 - 40.4 | 20.8 | 0.6 - 41.1 | - | - |
| New Mexico (SEER) | All stages | 7.0 | 4.3 - 9.7 | 6.9 | 4.0 - 9.7 | - | - | 9.7 | 7.1 - 12.4 | 9.9 | 7.0 - 12.9 | - | - |
| | Localized | 11.5 | 6.5 - 16.4 | 11.6 | 6.3 - 16.9 | - | - | 17.0 | 11.6 - 22.3 | 15.9 | 10.6 - 21.3 | - | - |
| | Regional | 2.3 | 0.0 - 5.6 | 0.0 | - | - | - | 0.0 | 0.0 - 0.0 | 2.2 | 0.0 - 5.2 | - | - |
| | Distant | 4.8 | 0.8 - 8.9 | 4.9 | 0.9 - 8.9 | - | - | 5.5 | 1.3 - 9.6 | 4.6 | 0.5 - 8.7 | - | - |
| | Unknown | 3.0 | 0.0 - 6.2 | 3.3 | 0.0 - 6.8 | - | - | 6.8 | 2.4 - 11.2 | 6.6 | 1.9 - 11.3 | - | - |
| Utah (SEER) | All stages | 11.4 | 6.5 - 16.3 | 11.7 | 6.5 - 17.0 | - | - | 9.8 | 5.9 - 13.7 | 10.7 | 6.4 - 15.0 | - | - |
| | Localized | 16.8 | 9.6 - 24.1 | 18.8 | 10.5 - 27.2 | - | - | 23.9 | 17.3 - 30.5 | 23.0 | 16.1 - 29.8 | - | - |
| | Regional | 12.5 | 1.8 - 23.2 | 8.9 | 0.0 - 19.2 | - | - | 2.9 | 0.0 - 7.4 | 3.4 | 0.0 - 8.8 | - | - |
| | Distant | 0.0 | - | 0.0 | - | - | - | 1.0 | 0.0 - 3.4 | 1.2 | 0.0 - 4.0 | - | - |
| | Unknown | 5.5 | 0.0 - 13.9 | 6.1 | 0.0 - 15.4 | - | - | 0.0 | - | 0.0 | - | - | - |
| Wyoming (NPCR) | All stages | 2.7 | 0.0 - 7.0 | 3.0 | 0.0 - 7.6 | - | - | 8.1 | 2.2 - 13.9 | 8.1 | 2.3 - 14.0 | - | - |
| | Localized | - | - | - | - | - | - | 15.9 | 5.3 - 26.6 | 15.7 | 5.2 - 26.3 | - | - |
| | Regional | - | - | - | - | - | - | - | - | - | - | - | - |
| | Distant | - | - | - | - | - | - | - | - | 0.0 | - | - | - |
| | Unknown | 0.0 | - | 0.0 | - | - | - | 6.5 | 0.0 - 15.9 | 6.8 | 0.0 - 16.6 | - | - |
| Pacific | | | | | | | | | | | | | |
| Alaska (NPCR) | All stages | 9.0 | 3.9 - 14.0 | 9.8 | 2.6 - 17.0 | - | - | 16.6 | 9.4 - 23.7 | 13.1 | 6.9 - 19.4 | - | - |
| | Localized | 26.1 | 10.1 - 42.0 | 22.0 | 2.0 - 42.0 | - | - | 34.8 | 20.4 - 49.2 | 46.1 | 29.1 - 63.2 | - | - |
| | Regional | 4.6 | 0.0 - 11.6 | 7.8 | 0.0 - 19.4 | - | - | 3.0 | 0.0 - 7.5 | 4.8 | 0.0 - 12.0 | - | - |
| | Distant | 5.6 | 0.0 - 14.1 | 10.0 | 0.0 - 24.6 | - | - | 0.0 | 0.0 - 0.0 | 0.1 | 0.0 - 0.5 | - | - |
| | Unknown | 7.5 | 0.0 - 16.2 | 4.1 | 0.0 - 10.4 | - | - | 10.0 | 0.0 - 21.9 | 0.0 | 0.0 - 0.0 | - | - |
| California (NPCR/SEER) | All stages | 11.4 | 10.6 - 12.3 | 10.1 | 9.1 - 11.1 | 7.2 | 5.1 - 9.3 | 14.8 | 13.8 - 15.8 | 12.8 | 11.7 - 13.9 | 11.7 | 8.5 - 14.9 |
| | Localized | 21.8 | 20.0 - 23.6 | 18.9 | 16.8 - 20.9 | 13.9 | 9.1 - 18.7 | 26.1 | 24.1 - 28.0 | 22.6 | 20.4 - 24.8 | 25.1 | 19.0 - 31.3 |
| | Regional | 7.8 | 6.4 - 9.2 | 7.5 | 5.7 - 9.3 | 5.0 | 2.1 - 7.8 | 10.1 | 8.6 - 11.6 | 8.8 | 7.1 - 10.4 | 5.9 | 2.3 - 9.5 |
| | Distant | 1.9 | 1.1 - 2.6 | 1.8 | 0.9 - 2.8 | 3.4 | 0.0 - 7.0 | 1.7 | 1.0 - 2.4 | 1.4 | 0.7 - 2.1 | 3.3 | 0.7 - 5.9 |
| | Unknown | 3.8 | 2.5 - 5.1 | 3.9 | 2.3 - 5.5 | 1.1 | 0.0 - 2.4 | 5.8 | 4.2 - 7.3 | 5.5 | 3.7 - 7.3 | 4.4 | 0.0 - 10.3 |
| Hawaii (SEER) | All stages | 15.2 | 11.3 - 19.1 | 19.8 | 8.4 - 31.1 | - | - | 13.2 | 8.8 - 17.6 | 16.8 | 9.0 - 24.7 | 21.8 | 0.0 - 44.9 |
| | Localized | 31.4 | 23.9 - 38.9 | 43.2 | 21.5 - 65.0 | - | - | 27.0 | 18.7 - 35.3 | 31.4 | 11.1 - 51.6 | - | - |
| | Regional | 6.9 | 2.7 - 11.2 | 5.9 | 0.0 - 14.9 | - | - | 4.5 | 0.0 - 10.0 | 11.6 | 1.4 - 21.8 | - | - |
| | Distant | 1.0 | 0.0 - 2.1 | - | - | - | - | 1.4 | 0.0 - 3.4 | 5.4 | 0.0 - 12.7 | - | - |
| | Unknown | 0.0 | - | - | - | - | - | 0.1 | 0.0 - 0.3 | 7.5 | 0.0 - 18.2 | - | - |

Cancer

| SEER Summary Stage | 2001-2003 | | | | | | 2004-2009 | | | | | | |
|--------------------------|------------|--------|-------------|--------|-------------|--------|------------|--------|-------------|--------|-------------|--------|------------|
| | All races | | White | | Black | | All races | | White | | Black | | |
| | NS (%) | 95% CI | NS (%) | 95% CI | NS (%) | 95% CI | NS (%) | 95% CI | NS (%) | 95% CI | NS (%) | 95% CI | |
| Oregon (NPCR) | All stages | 6.9 | 4.3 - 9.5 | 5.9 | 3.3 - 8.5 | - | - | 11.2 | 8.7 - 13.8 | 10.1 | 7.4 - 12.8 | 6.3 | 0.0 - 15.3 |
| | Localized | 13.4 | 6.8 - 20.0 | 10.5 | 4.2 - 16.8 | - | - | 22.8 | 16.9 - 28.7 | 20.0 | 14.0 - 26.0 | 0.0 | 0.0 - 0.1 |
| | Regional | 8.0 | 2.6 - 13.3 | 10.1 | 3.5 - 16.8 | - | - | 7.9 | 4.5 - 11.3 | 7.2 | 3.6 - 10.7 | 0.1 | 0.0 - 0.2 |
| | Distant | 1.9 | 0.0 - 4.0 | 2.2 | 0.0 - 4.5 | - | - | 2.8 | 0.1 - 5.4 | 3.9 | 0.7 - 7.0 | - | - |
| | Unknown | 3.6 | 0.7 - 6.5 | 2.0 | 0.0 - 4.1 | - | - | 4.2 | 0.5 - 8.0 | 3.7 | 0.4 - 7.0 | - | - |
| Washington (NPCR) | All stages | 11.8 | 9.5 - 14.1 | 10.7 | 8.1 - 13.2 | 12.3 | 1.6 - 23.1 | 14.7 | 12.4 - 17.0 | 13.9 | 11.3 - 16.4 | 8.1 | 4.6 - 11.7 |
| | Localized | 23.9 | 18.9 - 28.8 | 24.4 | 18.7 - 30.1 | 22.9 | 1.7 - 44.0 | 28.1 | 23.1 - 33.0 | 28.2 | 22.7 - 33.7 | 13.2 | 0.0 - 27.5 |
| | Regional | 6.4 | 3.5 - 9.4 | 4.1 | 1.5 - 6.6 | 6.8 | 0.0 - 17.0 | 7.4 | 4.8 - 10.1 | 5.3 | 2.9 - 7.8 | 5.5 | 0.0 - 12.9 |
| | Distant | 1.9 | 0.3 - 3.6 | 1.6 | 0.1 - 3.1 | - | - | 0.9 | 0.0 - 2.2 | 1.2 | 0.0 - 2.7 | - | - |
| | Unknown | 1.5 | 0.0 - 3.0 | 1.8 | 0.0 - 3.6 | - | - | 5.6 | 2.4 - 8.9 | 5.1 | 1.7 - 8.5 | - | - |

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60